

1 **Integrating Perspectives in Actinomycete Research: an ActinoBase**
2 **Review of 2020-21**

3 **Authors**

4 Agustina Undabarrena¹, Camila F. Pereira^{2†}, Worarat Kruasuwan^{3†}, Jonathan Parra^{4†}, Nelly
5 Sélem-Mojica^{5†}, Kristiina Vind^{6,7†}, Jana K Schniete^{8*}

6 † Authors contributed equally to this work

7 **Author Affiliations**

8 ¹Laboratorio de Microbiología Molecular y Biotecnología Ambiental, Departamento de Química & Centro
9 de Biotecnología Daniel Alkalay Lowitt, Universidad Técnica Federico Santa María, Valparaíso 2340000,
10 Chile.

11 ²School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil

12 ³Microbial Cell Factory Research Team, National Center for Genetic Engineering and Biotechnology,
13 National Science and Technology Development Agency, 113 Thailand Science Park, Khlong Nueng, Khlong
14 Luang, Pathum Thani 12120, Thailand

15 ⁴Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE,
16 United Kingdom

17 ⁵Centro de Ciencias Matemáticas, Antigua Carretera a Pátzcuaro # 8701, Col. Ex Hacienda San José de la
18 Huerta, Morelia C.P. 58089, Michoacán, México

19 ⁶NAICONS Srl, Viale Ortles 22/4, 20139 Milan (MI), Italy

20 ⁷Host-Microbe Interactomics Group, Wageningen University, De Elst 1 6708 WD, Wageningen, The
21 Netherlands

22 ⁸Biology, Edge Hill University, St Helens Road, Ormskirk, L39 4QP, United Kingdom

23 **Correspondence:** Jana K Schniete, schnietj@edgehill.ac.uk

24

25 **Abstract**

26 Last year ActinoBase, a Wiki-style initiative supported by the UK Microbiology Society, published a review
27 highlighting the research of particular interest to the actinomycete community. Here, we present the
28 second ActinoBase review showcasing selected reports published in 2020 and early 2021, integrating
29 perspectives in the actinomycete field.

30 Actinomycetes are well-known for their unsurpassed ability to produce specialised metabolites, of which
31 many are used as therapeutic agents with antibacterial, antifungal, or immunosuppressive activities.
32 Much research is carried out to understand the purpose of these metabolites in the environment, either
33 within communities or in host interactions. Moreover, many efforts have been placed in developing
34 computational tools to handle big data, simplify experimental design, and find new biosynthetic gene
35 cluster prioritisation strategies. Alongside, synthetic biology has provided advances in tools to elucidate
36 the biosynthesis of these metabolites. Additionally, there are still mysteries to be uncovered in
37 understanding the fundamentals of filamentous actinomycetes' developmental cycle and regulation of
38 their metabolism.

39 This review focuses on research using integrative methodologies and approaches to understand the bigger
40 picture of actinomycete biology, covering four research areas: *i)* technology and methodology; *ii)*
41 specialised metabolites; *iii)* development and regulation; and *iv)* ecology and host interactions.

42 **Keywords:** ActinoBase; Actinobacteria; development; integrating perspectives; methodology; microbial
43 ecology; natural products; regulation; specialised metabolites; *Streptomyces*.

44

45 **Abbreviations**

46 **AAA**, aromatic amino acids; **antiSMASH**, antibiotics and secondary metabolites analysis shell; **antiSMASH-**
47 **DB**, antiSMASH database; **BGC**, biosynthetic gene cluster; **BiG-SCAPE**, biosynthetic gene similarity
48 clustering and prospecting engine; **BiG-SLiCE**, Biosynthetic Genes Super-Linear Clustering Engine; **cAMP**
49 cyclic adenosine monophosphate; **c-di-GMP**, bis-(3',5')-cyclic di-guanosine monophosphate; **ChIP-seq**,
50 chromatin immunoprecipitation sequencing; **DGC**, diguanylate cyclase; **EAD**, electrophysiological
51 antennal detection; **ESKAPE**, *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*,
52 *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Enterobacter* spp. ; **FA**, fatty acids; **GBL**, γ -
53 butyrolactone; **GC**, gas chromatography; **GCF**, Gene Cluster Family; **GNPS**, Global Natural Products Social
54 molecular networking; **GPA**, glycopeptide antibiotic; **HMM**, Hidden Markov Models; **IMG-ABC**, Integrated
55 Microbial Genomes Atlas of Biosynthetic Gene Clusters; **iTOL**, interactive tree of life; **LC-MS/MS**, Liquid
56 Chromatography-Tandem Mass Spectrometry; **MAG**, metagenome-assembled genomes; **MIBiG**,
57 Minimum Information about a Biosynthetic Gene Cluster; **MF**, Molecular family; **NMR**, nuclear magnetic
58 resonance; **NP**, natural product; **NRPS**, non-ribosomal peptide synthetase; **OSMAC**, one strain many
59 compounds approach; **PDE**, phosphodiesterase; **PFGE**, pulsed-field gel electrophoresis; **PGP**, plant
60 growth-promoting; **PKS**, polyketide synthase; **QS**, quorum sensing; **RiPP**, ribosomally synthesized and
61 post-translationally modified peptide; **RNA-seq**, RNA-sequencing; **SM**, specialised metabolite; **TCA**,
62 tricarboxylic acid cycle; **TX-TL**, transcription-translation; **VOC**, volatile organic compound
63

64 Introduction

65 ActinoBase (<https://actinobase.org>) was established in 2019 with the support of the UK Microbiology
66 Society as a Wiki-style initiative for the actinomycete research community. It aims to create a communal
67 space to distribute knowledge and resources. Last year, ActinoBase published a review highlighting ten
68 publications of important contributions to the field from 2019 [1]. This second review showcases 14
69 articles that integrate perspectives in actinomycete research from 2020 and early 2021, covering four
70 main areas: *i*) technology and methodology; *ii*) specialised metabolites; *iii*) development and regulation;
71 and *iv*) ecology and host interactions (**Figure 1**).

72 Actinobacteria are Gram-positive high GC content bacteria, with a diverse range of morphologies ranging
73 from unicellular cocci or rods to multicellular filamentous hyphae and spore-forming organisms
74 depending on their genera [2]. They are widely distributed across ecosystems, ubiquitous in soil and water
75 habitats, and can live in symbiosis with higher eukaryotes [3]. A striking feature of actinomycete is that
76 they produce chemically diverse specialised metabolites (SMs). SMs are compounds not essential for
77 maintenance and growth, but often play a critical role in interspecies interactions [4]. Additionally, many
78 SMs are of therapeutical value [5], constituting a rich resource for drug discovery [6]. SMs are often
79 referred to as natural products (NPs) as well, this wider term encompasses any compound made by a
80 living organism. Due to the current antimicrobial crisis, there is a need to improve the finding of novel
81 antibiotics from actinomycetes, by developing advances in the detection/production pipeline, and
82 applying integrative approaches to unveil SMs function [7]. For instance, SMs production in *Streptomyces*
83 is linked to its life cycle [8–10], highlighting the importance of understanding its complex developmental
84 regulation [11].

85 SMs are genetically encoded small molecules produced by a group of co-occurring genes referred to as
86 biosynthetic gene clusters (BGCs), involved in synthesising one or more structurally-similar molecules [5,
87 12]. The genomic era has opened a new roadmap for the study of BGCs with genome mining as a
88 prominent strategy to find candidates for novel bioactive compounds [4, 13, 14]. This has allowed
89 researchers to uncover thousands of new BGCs of different classes, including polyketides (PKs); non-
90 ribosomal peptides (NRPs) [15–18]; PK-NRP hybrid compounds; ribosomally synthesized and post-
91 translationally modified peptides (RiPPs) such as lanthipeptides or thiopeptides [19–21]; and volatile
92 organic compounds (VOCs) [22, 23]; among others [24–28].

93 Although genomics has revealed key elements of SMs biosynthesis, there are still challenges to overcome.
94 Their low production, the rediscovery of known compounds, and a general lack of understanding of the
95 role of these compounds in nature, as well as the fact that many organism remain unculturable [29, 30].
96 Moreover, many computational tools for high-throughput data mining have been developed to support
97 BGCs prioritisation and dereplication [31]. Handling big data requires prioritisation to establish selection
98 criteria for certain BGCS based on the specific research context. [32]. Dereplication is selecting a BGCS
99 based on its novelty, often achieved by comparing with databases such as Minimum Information about a
100 Biosynthetic Gene Cluster (MIBiG) [33, 34].

101 Additionally, advances in synthetic biology have improved the genetic manipulation of actinomycetes,
102 helping to characterize and functionally validate BGCs predictions [35–37]. Furthermore, engineering
103 BGCs has been crucial to unlocking their potential since most BGCs are silent or cryptic under controlled
104 laboratory conditions [38]. Recent definitions for cryptic and silent BGCS describe cryptic as a BGCS where
105 the compound is unknown, but its biosynthesis is not; and silent as the compound is undetectable [38].
106 In this context, understanding actinomycete relationships with the environment and other organisms is a
107 crucial factor when searching for BGCs elicitors, referred to as molecules or signals that can trigger the
108 expression of a certain BGCs [11].

109 Currently, integrative approaches are used to fill these knowledge gaps, which ultimately deepen our
110 understanding of actinomycete biology. This trend is the central theme of this review, which highlights
111 recent studies from 2020 and early 2021 that integrated genomic, metabolomic, transcriptomic, genetic
112 engineering, and ecological data to provide significant insights in actinomycete research. (**Figure 1**).

113 I. Technology and Methodology

114 Stagnation in the traditional SMs discovery pipeline has motivated researchers to develop novel strategies
115 for compound discovery [7]. The boost in sequencing has guided genome-based predictions of BGCs with
116 tools such as antiSMASH for BGCs classification, according to their core enzymes [39]. Similarly, PRISM
117 [40], BAGEL [41] or RiPPMiner [42] are complementary mining tools, and a complete list is available here
118 <http://www.secondarymetabolites.org/mining/>. Development of community resources such as MIBiG
119 repository have been essential for deposit functionally characterised BGCs data in a standardised manner
120 [34]. A continuous challenge is to interpret BGCs in terms of their novelty and function, for which tools
121 facilitating their comparison applied to large data sets have invigorated clinically relevant SMs discovery.
122 Two of these recent tools, BiG-SCAPE [43] and Global Natural Product Social Molecular Networking (GNPS)
123 [44], enable building of interactive similarity networks of BGCs and SMs, respectively. While grouping of
124 BGCs is according to sequence similarity, the grouping of SMs is by mass spectrometry fragmentation
125 patterns (MS/MS). In the past year, these tools have been expanded by the release of BiG-SLiCE [8], BiG-
126 FAM [45] and Qemistree [46], allowing further refinement of big data exploration, which we have selected
127 to address in detail below. A comprehensive general review of the latest bioinformatics development is
128 also offered in Medema (2021) [47].

129 In parallel, the field has encountered important methodological advances in synthetic biology. This
130 complementary approach is simplifying the experimental testing of the hypotheses derived from
131 computational predictions. Actinomycete are often hard to genetically manipulate: some exhibit low
132 intrinsic recombination frequencies, are slow-growers, or fail to sporulate; thus, many efforts go to
133 delivering or adapting new tools for their genetic manipulation [48]. Traditionally PCR based technologies
134 such as ReDIRECT [49] have been complemented or replaced by other methods such as the meganuclease
135 I-SceI from *Saccharomyces cerevisiae* [50] for the use in novel and genetically uncharacterised
136 actinomycete; the adaptation of the CRISPR-Cas9 system through the development of pCRISPOmyces [36];
137 and more recently to the CRISPR-BEST system [51], which allows genome manipulation without the
138 introduction of a double-strand break, highlighted in last year's ActinoBase review [1].

139 Another challenge in metabolic engineering is that engineered strains frequently become less fit due to
140 unforeseen metabolic constraints and imbalances, necessitating individual and optimisation for each
141 strain and heterologous cloned BGC. Thus, the characterisation of new biosynthetic pathways becomes a
142 very time consuming and laborious process when testing expression in different heterologous hosts. A

143 detailed review focussing on synthetic biology advances in *Streptomyces* can be found at Breitling *et al.*
144 [37].

145 To have a toolbox of entirely synthetic systems controllable for each subclass of BGCs would allow a more
146 streamlined screening of the large amount of cryptic and silent gene clusters that we observe in the *in*
147 *silico* analyses [52]. We have chosen to highlight two articles with important advances in these topics: an
148 optimised cell-free transcription-translation one-pot reaction that circumvents heterologous hosts'
149 incompatibility and bring us a step closer to the above-mentioned synthetic biology toolbox [54]; and the
150 combination of a quorum-sensing mechanism inside a CRISPRi circuit, allowing a dynamic metabolic
151 engineering approach [53].

152

153 **BiG-SLiCE: A highly scalable tool maps the diversity of 1.2 million biosynthetic gene clusters [8]**

154 One approach to understanding the vast diversity and taxonomic distribution of BGCs is through their
155 comparative study. Homologous BGCs are hypothesized to produce similar SMs, which can be grouped
156 based on sequence similarity into gene cluster families (GCFs). The first tool to accomplish this was BiG-
157 SCAPE which allowed calculation of pairwise distances between BGCs and mapped them onto interactive
158 sequence similarity networks [43]. However, the amount of computing power required by this algorithm
159 was a drawback to scale up from thousands to millions of BGCs. To address this problem, BiG-SLiCE was
160 developed [8]. In contrast to the detailed BiG-SCAPE classification, BiG-SLiCE manages big data by
161 representing BGCs in the Euclidean space, grouping them in non-linear and non-pairwise fashion. In this
162 way, this powerful clustering platform manages to roughly organise 1,225,071 BGCs from genomes and
163 metagenome-assembled genomes (MAGs) in just ten days.

164

165 BiG-SLiCE operates by finding a set of 121,299 BGCs as centres of GCFs after the first round of clustering,
166 assigning BGCs to its corresponding family by considering the minimal distance to these centroids. For
167 centroids determination, BiG-SLiCE firstly encodes BGCs into a numerical vector capturing the presence
168 of selected domains from a curated set of Hidden Markov Models (HMM) from the Pfam database [54].
169 Subsequently, the BIRCH superlinear clustering algorithm is applied to these numerical vectors to define
170 family profiles [55], and the average vector of the cluster will be determined as the centroid. Centroids
171 are then directed to the second round of clustering, using the K-mean algorithm to allow visualisation in
172 a species tree [56]. As a result, families are grouped into 500 bigger sets called bins. Afterwards, every

173 BGC is mapped to the closest centroid of these bins and are further classified. Finally, SQLite is used to
174 store this data and allow new BGCs searches (<https://www.sqlite.org/index.html>), while R and python
175 scripts are provided as visualisation tools.

176

177 For the first time, a global map of biosynthetic diversity was created thanks to BiG-SLiCE: 121,299
178 centroids from the first round of clustering were grouped into 500 bins, and finally, 1.2 million BGCs were
179 mapped onto these. The 500 bins are displayed in a hierarchical tree allowing exploration of their
180 distribution across different taxa. While *Streptomyces* confirms its status among the genera with the
181 greatest BGCs potential, other members of *Actinobacteria* and *Ascomycota*, *Firmicutes*, and
182 *Proteobacteria* phyla also appear among those bearing important biosynthetic potential. BiG-SLiCE also
183 estimates that only 3.7% of the GCFs are closely related to the characterised MIBiG BGCs, highlighting the
184 unknown chemistry that remains uncovered. Another advantage of BiG-SLiCE is that it allows to rapidly
185 locate a new BGCs of interest via a simple search mode in the pre-calculated families stored in the BiG-
186 FAM database.

187

188 Although BiG-SLiCE was developed to reveal the uncharted biosynthetic potential, it is based solely on
189 antiSMASH-predicted BGCs, and a selection of biosynthetic Pfam domains was used for the construction
190 of the GCFs models. Consequently, genomic vicinities predicted by other algorithms, or BGCs lacking the
191 specifically selected domains, would be left out of the analysis. Hopefully, this will improve in the future.
192 Moreover, due to gene content or sequence variation, each GCF may be subdivided into subsets of BGCs
193 that produce different metabolites. The number of different products by family may differ as well as the
194 genetic variation rate. A remaining challenge is to incorporate different thresholds to integrate each
195 family, considering the chemical variation of its produced metabolites.

196

197 **BiG-FAM: the biosynthetic gene cluster families database [45]**

198 The increasing availability of BGCs data created the problem of understanding their diversity on a new
199 computational scale. Specific BGCs databases, such as antiSMASH-DB [57] and IMG-ABC [58], can display
200 similarity to the MIBiG repository. However, they do not consider a metric of distance to homologous
201 BGCs conforming GCFs. Thus, there was a lack of a BGCs family database, now fulfilled by the development
202 of BiG-FAM [45]. While BiG-SLiCE solved the problem of defining a metric and algorithm in feasible
203 computational time that allow the classification of the millions of currently available BGCs into GCFs, the
204 BiG-FAM database acts as a repository to display BiG-SLiCE results.

205

206 In BiG-FAM, SQL is used to provide fast searches (*i.e.*, 0.5 seconds) from BiG-SLiCE pre-calculated families,
207 while Python/R scripts and flask libraries (Python-based web framework) provide a user-friendly interface.
208 BiG-FAM goes beyond a storage and consulting website, as it allows exploring taxonomic distributions by
209 including a web-based query function for users to match their own antiSMASH predicted BGCs onto GCFs,
210 which reveals the closest and distant relatives of the queried BGCs. Meaning that a BGC of interest, not
211 included in the BiG-SLiCE calculation, could easily be situated in BiG-FAM families without the necessity
212 of calculating the distance between the BGC of interest and every other BGC represented in BiG-FAM.
213 Subsequently, BiG-SLiCE can calculate the closest centroid and finally, classify the BGC of interest into the
214 corresponding family. Another advantage of BiG-FAM it includes functionally characterised BGCs from
215 MIBiG, accessible by either using a taxonomy search or other filters of interest. The BiG-FAM result is
216 displayed as an interactive platform by providing graphic visualisation of Pfam domains within each gene
217 and creating a word cloud to show the abundance of these domains.

218

219 Authors showcase BiG-FAM with two examples. First, a ranthipeptide (*i.e.*, radical non- α thioether
220 containing peptides) RIPP BGCs diversity was explored, where ranthipeptide genetic neighbourhood and
221 the precursors needed for its biosynthesis were discovered using a comparative visualisation. Secondly,
222 BGCs assignment into GCFs from a newly sequenced *Streptomyces* strain was carried out, and the novelty
223 of 'Region 15.1' BGC was explored by localizing its family. Using ClusterBlast, this BGC showed low levels
224 of similarity against public databases, consistent with BiG-FAM results, which showed it as a singleton.

225

226 BiG-FAM allows similarity searches by adding of another layer of comparison, such as domain architecture,
227 which can add knowledge into more distant BGCs relationships. It can explore homologous BGCs as
228 families and furthermore, it can place BGC of interest within these families. BiG-FAM opens the door to
229 address questions regarding the composition and variation within these families, and their analysis
230 regarding conservation. Nevertheless, as BiG-FAM is not a BGCs database, it does not provide BGC specific
231 details, only family information. Pre-calculation and previous knowledge are required to define
232 parameters such as the minimum set of domains that allow vectorization of BiG-SLiCE, and it can be a
233 drawback when analysing underrepresented clades, such as Archaea, which genomes are one order of
234 magnitude below other domains. Thus, results might be biased towards overrepresented groups.

235

236 An important issue that remains for future work is to understand how to apply these algorithms to other
237 biological processes involving gene clusters, such as operons from central metabolism or unknown BGC
238 classes. The ability to classify and map processes other than specialised metabolism in this way would
239 increase our understanding of specialised metabolite producers. Additionally, metadata such as
240 geographic or ecological distribution of the BGCs families could be incorporated into the database, as it
241 could help answer evolutionary, genomic, and ecological questions regarding BGCs.

242

243 **Chemically informed analyses of metabolomics mass spectrometry data with Qemistree [46]**

244

245 While BiG-SLiCE and BiG-FAM rely on genomic input, metabolomics has also encountered the necessity
246 to develop tools to access big data to extract meaningful information. For instance, GNPS molecular
247 networking [44] allows MS/MS comparison to visualise their relations in discrete molecular families (MFs).
248 In contrast to classical molecular networking, Qemistree enables exploring the relatedness of all features
249 in the dataset. Qemistree is a tree-based metabolomics visualisation tool for tandem MS data from
250 untargeted metabolomics experiments, hierarchically representing chemical features, analogous to
251 phylogenetic tree building for sequences.

252 The pipeline utilises chemical feature detection [59] followed by SIRIUS [60, 61] to determine each
253 feature's molecular formula, and using the fragmentation pattern to estimate the best fragmentation
254 tree. In the next step, CSI: FingerID [62] uses those fragmentation trees and kernel support vector
255 machines to predict molecular properties resulting in molecular fingerprints. Pairwise distances are then
256 calculated and hierarchically clustered to generate a tree representing structural relationships. Finally,
257 ClassyFire [63] can assign chemical taxonomy and iTOL acts as a visualisation tool for the resulting tree
258 [64]. The software pipeline is freely available either as a QIIME2 plugin [65] or GNPS networking flow [66].

259 The authors utilise three different approaches to evaluate the tool by case studies. The first one attempts
260 to demonstrate Qemistree's advantage over traditional analysis tools relying on molecular fingerprints,
261 independent of retention time shifts that could result from differing elution conditions. The second one
262 shows that the tree-based analysis using chemical relatedness can detect similarities among different
263 samples, where traditional methods often lead to an over-assumption of differences. Last, a
264 heterogeneous dataset was obtained, showing that the chemical features agreed with ClassyFire,
265 confirming that molecular fingerprints are a suitable marker.

266 Qemistree relies on molecular fingerprints and their prediction is limited to the quality and coverage
267 available in MS/MS spectral databases. In the future, it will be interesting if the concept of Qemistree can
268 be applied on other chemical relationship markers such as chemical classes, spectral motifs and shared
269 biosynthetic origins, however this will require further benchmarking to assess when to use which
270 approach.

271 Overall, Qemistree is universally applicable and a readily available tool to interpret and visualize complex
272 metabolomics data. As GNPS is already widely used in the actinomycete community, this additional
273 feature in the pipeline will be of value to compare samples from different taxa and/or environments to
274 discover novel chemical diversity and aid dereplication challenges at a large scale, like the Earth
275 Microbiome project [67]. Moreover, it adds another layer of understanding, taking into consideration
276 molecular relatedness in addition to the genetic one.

277 **A *Streptomyces venezuelae* Cell-Free Toolkit for Synthetic Biology [68]**

278 Cell-free systems are powerful tools in synthetic biology, allowing a controlled and simplified environment
279 to study specific cellular processes in the absence of the entirety and complexities of cells [69]. Due to
280 mostly unknown regulatory circuits for silent BGCs, cell-free systems stand as an attractive and fast wet-
281 lab option to test hypotheses derived from computational predictions.

282 Moore *et al.* introduce an optimised cell-free transcription-translation (TX-TL) system tailored for studying
283 *Streptomyces* silent metabolic pathways. Cell-free TX-TL systems are crude cell extracts (or purified
284 ribosomes) containing translation factors and the respective DNA coding for the pathway of interest on a
285 plasmid in a buffered solution. Thus, it allows a quick and inexpensive way of studying transcription,
286 translation and biosynthesis in a “one-pot” reaction [70–72]. It offers a simplified and controllable
287 environment to study SMs by providing precursors for biosynthesis and direct control over feeding
288 precursors in short experimental time scales. Moreover, it is crucial for circumventing unknown regulatory
289 cascades by providing the genes of interest on a plasmid under the control of a chosen promoter.

290 A robust, high-yield *Streptomyces* TX-TL protocol is achieved by optimising temperature; pH; regulatory
291 elements (*i.e.*, promoter strength, start codon preference, terminator); energy solution (*i.e.*, NTP
292 concentration); ATP regeneration (*i.e.*, secondary energy sources); RNase inhibition (*i.e.*, polyvinyl sulfonic
293 acid (PVSA) concentration); DNA concentration and methylation, yielding at least 6-fold improvement to
294 the previous system with fewer batch variations.

295 Protein expression yields were assessed by codon optimised expression of genes for sfGFP, mVenus and
296 mScarlet as reporters using real-time detection, as well as the expression of the oxytetracycline enzymes
297 (*otc* cluster) from *S. rimosus*, and three NRPS genes (*txtA* and *txtB* from *S. scabiei*; and an unknown NRPS
298 from *S. rimosus*). Furthermore, they also studied the expression using a codon optimised GUS reporter
299 and two pathways from *S. venezuelae* DSM-40230: the copper metallochaperone (MelC1) and tyrosinase
300 (TyrC) from the melanin pathway, as well as the early-stage *haem* pathway (HemB, HemD-CysG, HemC).
301 In both cases, the TX-TL systems supported transcription, translation, and biosynthesis, as they observed
302 the brown pigment for melanin by UV light absorption and intermediate products from the *haem* pathway
303 by LC-MS analysis.

304 Overall, this work is a promising proof of concept for using cell-free extracts in SMs research, which may
305 lead to the characterisation of unknown BGCs from genome mining. However, further challenges remain
306 in applying it to environmental strains and other classes of specialised metabolites, where less *a priori*
307 knowledge is available. Nevertheless, this tool has potential for scalability that could lead to the chemical
308 purification and characterisation of new metabolites, circumventing incompatibilities with heterologous
309 hosts, a typical obstacle in traditional approaches [73].

310

311 **Developing an endogenous quorum-sensing based CRISPRi circuit for autonomous and** 312 **tunable dynamic regulation of multiple targets in *Streptomyces*** [53]

313 Traditional metabolic engineering often referred to as static metabolic engineering, mainly uses two
314 approaches to increase metabolite titres: either by deleting genes from competing pathways to force the
315 metabolic flux into a specific pathway, or by overexpressing key enzymes through engineering promoters
316 or ribosome binding sites [74]. However, this often results in an overall reduced strain fitness caused by
317 metabolic imbalances due to competition around cellular resources, leading to the accumulation of
318 certain undesired products and/or decreased growth rates. The formation of heterogenous
319 microenvironments inside large scale bioreactors can also lead to variable performance of statically
320 engineered strains. A comprehensive overview of the challenges can be found in Hartline *et al.* [75].

321 Dynamic metabolic engineering approaches attempt to create an autonomous response based on the
322 environmental factors or internal metabolic states. Tian *et al.* introduce a pathway-independent
323 regulation using a CRISPR-based tool with integrated quorum sensing (EQCi) to regulate multiple target

324 genes in *Streptomyces*. The quorum sensing component allows an autonomous and dynamic response by
325 the strain to its environment [76]. The authors designed an EQCi circuit to respond in a density-dependent
326 manner using a γ -butyrolactone (GBL) responsive promoter to drive dCas9 expression and a synthetic
327 promoter to regulate the transcription of guide RNAs (gRNAs) targeting genes of interest. GBLs are well-
328 known for playing a role as regulatory molecules for antibiotic production and development in
329 *Streptomyces* [77] which counteract the aforementioned challenges.

330 The system was validated with rapamycin, a polyketide produced by *S. rapamycinicus*, by perturbing three
331 key nodes in primary metabolism to shift metabolic fluxes toward enhanced rapamycin production: fatty
332 acid (FA) synthesis, tricarboxylic acid (TCA) cycle, and aromatic amino acid (AAA), which are competing
333 with the rapamycin biosynthetic pathway over precursor molecules such as malonyl-CoA and methyl-
334 malonyl-CoA. The EQCi-based individual repression of key genes in the TCA, FA and AAA resulted in
335 increased rapamycin titres and had little or no effect on cell growth. Validation of the EQCi circuit was
336 performed targeting three genes simultaneously on rapamycin production. Interestingly, the EQCi circuit
337 harbouring the gRNA combination of three genes generated the highest titre (~660%) of rapamycin
338 compared to controls. Repressing the transcript levels of these target genes confirmed that they were
339 dynamically regulated in a cell density-dependent manner.

340 Additionally, the applicability of the EQCi circuit was demonstrated with actinorhodin, a polyketide
341 produced by *S. coelicolor* [78]. Remarkably, the strain carrying the same EQCi system targeting *gltA* gene
342 (*sco2736*) from the TCA cycle showed ~850% more actinorhodin than the wild type [78].

343 In summary, incorporating both the QS system and CRISPRi allows an adjustable, completely autonomous,
344 and dynamic downregulation of single or multiple pathways leading to metabolic flux redirection, thus
345 increasing target product biosynthesis without further interventions. However, off-target effects of the
346 gRNAs may result in unforeseen changes in metabolic flux as various genes are silenced simultaneously.
347 The result may be an insufficient supply of metabolites for primary metabolism and lead to growth
348 retardation and lower production yields. Therefore, a way forward will be to conduct quantitative studies
349 where various gRNAs are created for each gene and using sequencing to determine the best position for
350 each gRNA for the desired level of expression. Such quantitative datasets could enable computational
351 models for gRNA placement. Overall, this tool holds the potential to become a universal technology for
352 other industrial microorganisms.

353 Taken together the development of both data analysis tools to mine the ever-increasing amount of
354 available data from genomes, transcriptomes, proteomes, and metabolomes along with the much-needed
355 advancement of synthetic biology tools and the adaptations of genetic manipulation methodologies
356 already available in other organisms, has improved and facilitated the study of the extensive metabolic
357 repertoire of actinomycete. These pioneer signs of progress have a major effect on the study of SMs. The
358 computational predictive tools and the experimental methods are intrinsically linked, as advancement in
359 the first informs the next step of development in the second. In the following sections, we addressed the
360 link between computational and synthetic biology approaches to understand development and regulation
361 of specialised metabolism, and their ecological interactions.

362 II. Specialised Metabolites

363 Actinomycetes have evolved a complex chemical language by synthesising diverse SMs detectable by the
364 presence of a high number of BGCs in their genomes [5]. For bioprospecting novel SMs, considerable
365 resources have been invested in pursuing unique reservoirs and unveiling their striking features. For
366 instance, rare actinomycete, which represent less frequently isolated genera than *Streptomyces* [79], have
367 become established sources for structurally-diverse and chemically-unique SMs [80]. Special attention has
368 also been placed into marine actinomycete, where highly-bioactive novel taxa have been described, such
369 as *Salinispora* spp. [81, 82]. Furthermore, underexploited environments that drive unique evolutionary
370 pressures have also been recently investigated, such as polar regions [83], caves [84–86], and deserts [87–
371 89].

372 Combining omics technology, such as genome mining and untargeted metabolomics, offer powerful
373 means to gain insights into the natural role of SMs. One of the selected studies uses high-throughput
374 comparative genomics of the rare genus *Nocardia* to reveal how variations on BGCs reflected differences
375 in the chemical structure of the compounds [90]. We also discuss a second study where the chemical
376 potential of rare actinomycete from unusual habitats such as polar regions is explored, linking this
377 chemical potential to their genomic information through the novel tool NPLinker [91].

378 The availability of big data has encouraged the design of new mining tools for uncommon BGCs classes
379 enabling novel insights into SMs. This is the case for our selected paper that describes one novel approach
380 based on phylogenetic relationships and evolutionary divergence within a gene cluster to guide the
381 subsequent experimental rationale [92]. Moreover, the chemical-reverse approach can also be
382 informative, which takes compound elucidation as the starting point to go backwards and attempt to link
383 its production to the responsible BGC [93]. Altogether, these different approaches increase the likelihood
384 of discovering new BGCs to access the chemical uniqueness of their respective products, both crucial to
385 discovering novel SMs.

386 **Comparative genomics and metabolomics in the genus *Nocardia* [90]**

387 A valuable approach to studying rare actinomycete relies on performing a deeper investigation of a
388 promising genus through high-throughput comparative genomics and metabolomics of closely related
389 species. Männle *et al.* applied genomic tools to predict molecules produced by BGCs and compare the
390 findings with metabolomics data to identify chemical divergences in the structure of the compounds

391 related to variations in the BGCs. Although still a major challenge, authors merged several data sets
392 obtained from different techniques and tools, such as antiSMASH, BiG-SCAPE, LC-MS/MS, GNPS, and NMR,
393 by studying a conserved metabolic pathway from *Nocardia* strains.

394 First, phylogenetic inferences of over 100 *Nocardia* genomes from diverse sources were constructed
395 based on conserved housekeeping genes, retrieving six major clades. Correlation between BGCs
396 abundance and the respective clades was observed, and BGCs diversity was further investigated by
397 applying BiG-SCAPE. As several GCFs were widespread in *Nocardia* genomes, authors focused on a
398 conserved cluster predicted to produce nocobactin-like siderophores. Strict adjustment of BiG-SCAPE
399 threshold similarity parameters resulted in the formation of gene clusters subfamilies. Thus, it was
400 possible to observe that each subfamily of clusters had divergence in their metabolic pathway genes.
401 Compounds biosynthesized by the BGCs of these subfamilies were predicted, and 12 *Nocardia* strains
402 were cultivated to analyse their metabolomics profile through LC-MS/MS.

403 Furthermore, a molecular network was constructed using the GNPS platform, and correlated with the
404 GCFs network. Analysis of detected ions led to the identification of nocobactin-like compounds based on
405 fragmentation patterns and NMR data. These experimental results supported the bioinformatic
406 predictions, allowing the assignment of BGC candidates to derivatives of known compounds. Also, a
407 *Nocardia* strain was identified that might produce previously undescribed nocobactin variants.

408 Although the authors successfully correlated the prediction and identification of various nocobactin-type
409 compounds, they could not detect these molecules from two *Nocardia* species that bear the biosynthetic
410 capacity (*i.e.*, *N. araoensis* NBRC 100135 and *N. takedensis* NBRC 100417). Instead, they discovered that
411 these strains produce mycobactins, which leaves room for further research. This study is a promising
412 example of developing the genomic-driven discovery of new compounds in conserved biosynthetic
413 pathways. It demonstrates that through computational predictions and wet-lab experiments, BGCs
414 investigation by similarity networks can predict structural variations in SMs.

415 **Comparative metabologenomics analysis of polar Actinomycetes [91]**

416 Although computational networking approaches such as GNPS and BiG-SCAPE are widely used tools for
417 large-scale metabolomics and BGCs data analyses, respectively, the importance of linking these datasets
418 is just beginning to be recognized [94]. In this sense, Soldatou *et al.* applied the novel platform NPLinker

419 [95], an unsupervised method for integrating paired omics data, to establish links between complex
420 metabolomics and genomics datasets relating to marine polar actinomycetes [91].

421 In a previous report, authors' investigated the diversity of strains in marine sediments from the Arctic and
422 Antarctic using culturable and metagenomics approaches, which leads to a collection of 50 actinomycete
423 strains [83]. Soldatou *et al.* went a step further into exploring the chemical potential of twenty-five strains
424 of these phylogenetically and geographically diverse polar rare actinomycetes. In an attempt to discover
425 chemical diversity, underexplored genera -in comparison to *Streptomyces* [79]- were selected, including
426 *Pseudonocardia* spp., *Micrococcus* spp., *Rhodococcus* spp., and *Microbacterium* spp. By applying the one
427 strain many compounds approach (OSMAC), a collection of 100 extracts was produced and analysed via
428 LC-MS/MS. Then, the distribution of parent ions as an equivalent of detected metabolites was correlated
429 to bioactivity against ESKAPE pathogens. However, it was found that bioactivity was not necessarily
430 related to the highest number of parent ions. A molecular networking analysis, which included the
431 MolNetEnhancer workflow [96], was carried out to assess the chemical diversity and cluster the paired
432 ions into MFs.

433 Additionally, genome mining for 17 strains sequenced by Illumina technology revealed a total of 133 BGCs,
434 where 67% showed none or low homology to the MIBiG repository [97], suggesting novelty on the
435 biosynthetic potential of the analysed strains. After clustering the BGCs into GCFs using BiG-SCAPE,
436 NPLinker was used to suggest potential links between GCFs and MFs based on two standardised scoring
437 functions. This approach made it possible to predict four metabolites, including the known compounds
438 ectoine and chloramphenicol, whose experimental validation awaits to be confirmed.

439 Soldatou *et al.* show how the study of phylogenetically diverse polar actinomycetes can lead to the
440 discovery of novel chemistry. For instance, marine *Pseudonocardia* and *Rhodococcus* strains were
441 identified as potential sources of bioactive metabolites for further studies. Despite their interesting
442 bioactivity profile, *Pseudonocardia* strains were excluded from the genomic analysis due to difficulties in
443 assembling a complete genome from short reads, which would be interesting to cover in future.

444 Although one of the major limitations of the metabologenomic approach was the relatively low number
445 of publicly available experimental datasets, the proposed methodology proved to be an effective tool for
446 strain prioritisation, thus constituting a promising strategy for accelerating the discovery of novel
447 chemistry derived SMs. Undoubtedly, further integration of bioactivity with the paired omics data will

448 strengthen the possibility of identifying strains capable of producing new chemistry in future culture
449 collection screenings.

450 **Evolution-guided discovery of antibiotics that inhibit peptidoglycan remodelling [92]**

451 Big data analyses can be overwhelming, and thus prioritisation of BGCs to guide SMs discovery remains a
452 continuous challenge. One strategy to accomplish BGCs selection is phylogeny-guided, as biosynthetic
453 genes that diverge during evolution may produce compounds with new biological activity. An interesting
454 example was demonstrated for glycopeptide family (GPAs) antibiotics, where phylogenetic reconciliation
455 allowed us understand their origin and evolution [98]. Culp *et al.* investigate GPAs evolutionary dynamics
456 by constructing a phylogenetic analysis of all shared genes from BGCs of GPAs and highlighting the
457 evolutionary divergences observed in NRPS condensation domains [92]. Data were correlated with the
458 presence/absence of self-resistance genes, which unveiled that BGCs with resistance determinants are
459 commonly present in true GPAs and grouped into a single clade. Interestingly, two additional clades
460 lacking known GPA resistance genes were further studied: while one was found to be related to a known
461 compound called complestatin; the other had no associated molecule, leading to the isolation and
462 identification of a new compound, carbomycin.

463
464 Both compounds, complestatin and carbomycin, were experimentally demonstrated to be members of
465 the GPA family active against Gram-positive bacteria, including the vancomycin-resistant *Enterococcus* sp.
466 and other drug-resistant clinical strains. Moreover, the mechanism of action of these compounds was
467 described for the first time, showing they bind to peptidoglycan and block the autolysins enzyme action
468 that is essential for cell wall remodelling. These enzymes are responsible for peptidoglycan cleavage
469 during cell division and have a role in cell wall turnover [99]. Hence, blocking these enzymes results in
470 bacterial growth inhibition. In addition, despite attempts to select resistant mutants to both complestatin
471 and carbomycin compounds, resistance evolved slowly on the tested bacteria. Finally, topical lotions
472 containing both compounds were developed and tested *in vivo* against superficial infections in mice skin,
473 where it also was found to be effective in reducing bacterial growth.

474 Overall, this study demonstrates the potential of analysing BGCS evolutionary divergences for aiding and
475 guiding cluster prioritisation. When combined with the analysis of resistance determinants of a specific
476 antibiotic class, it can lead to discovering new compounds and novel mechanisms of action, contributing
477 to the advancement in the treatment of drug-resistant infections. Nevertheless, dealing with a novel

478 mode of action needs further investigation in the steps that are being blocked at the molecular level,
479 making the investigation even more challenging. However, this study stands as a light of hope to face the
480 rediscovery problem, not only due to the delivery of a novel antibiotic but also, elucidating modes of
481 action.

482 **A biaryl-linked tripeptide from *Planomonospora* reveals a widespread class of minimal RiPP**
483 **gene clusters [93]**

484 RiPPs have drawn attention due to their intricate three-dimensional structures and broad distribution
485 across actinomycete [20]. RiPPs BGCs encompass a gene encoding the precursor peptide and genes
486 encoding enzymes that modify that peptide. The precursor peptide is ribosomally synthesised, modified
487 by enzymes included in the corresponding RiPP BGCs and activated by cleavage of the N-terminal leader
488 peptide from the C-terminal core peptide [100]. Zdouc *et al.* discovered the smallest coding gene
489 described to date, belonging to a new class of RiPPs minimal BGCS which remained undetected using well-
490 established software pipelines.

491 Stemming from metabolomic studies of *Planomonospora* strains from Naicons' strain collection [101],
492 Zdouc *et al.* purified and elucidated the structure of a novel tripeptide with an unusual carbon-carbon (C-
493 C) bond between amino acids. The authors propose to call this novel class of compounds biarylittides, since
494 the products feature a C-C bridge between the aromatic amino acid residues. The gene cluster responsible
495 for such a product could not be identified using the antiSMASH platform, so a tailored approach was
496 needed to unveil the region coding for enzymes that produce biarylittides. Heterologous expression proved
497 that a minimal gene cluster consisting of only two genes is sufficient to develop the mature product
498 in a heterologous *Streptomyces* host. Biosynthesis was described as follows: first, the pentapeptide
499 precursor is ribosomally synthesized from the smallest gene ever to be described, *bytA*, accounting for
500 solely 18-base pairs. Then, the C-C bond between the aromatic moieties of the third and fifth amino acid
501 is carried out by *bytO*, coding for a cytochrome P450 monooxygenase. The cleavage of the two leading
502 amino acids and N-acetylation of the mature product are likely to be carried out by other enzymes from
503 central metabolism.

504 Surprisingly, bioinformatic analysis of 3,300 genome sequences revealed that the class of minimal RiPP
505 clusters described by Zdouc *et al.* are widely distributed across various actinomycete genera. However,
506 the biological role of this BGC and the product remains to be understood, as well as its applicability.

507 Investigating the mechanism and specificity of the biaryl crosslink might have important uses in stabilizing
508 peptides for different applications. This study highlights the importance of metabolomics-guided studies
509 in discovering novel BGC types, without the need for including bioactivity assays in the metabolite
510 prioritisation step to purify and describe an interesting compound. Undoubtedly, this study highlights the
511 usefulness of additional approaches for BGCs discovery alongside traditional genome mining tools, which
512 simply cannot predict unprecedented BGCs. Furthermore, this opens the road for their future
513 evolutionary and comparative genomic study.

514

515 Overall, these studies stand as solid examples of how integrating genomics and metabolomics data
516 analyses can provide unique insights that otherwise remain hidden when datasets are analysed
517 independently. Regarding rare actinomycetes, unique environments or not-so-common classes of
518 compounds like RiPPs or GPAs, are examples of how unconventional approaches may unveil new
519 opportunities for discover novel compounds. Moreover, the study of SMs needs to be considered as a
520 whole, understanding that while they might be important in the clinical setting, their primordial role
521 probably relies on a fundamental metabolic function within bacteria, which can be revealed through the
522 understanding of actinomycete's complex development, which will be discussed in the next section.

523 III. Development and Regulation

524 Unlike other bacteria, filamentous actinomycetes such as *Streptomyces*, possess a strikingly complex life
525 cycle. Briefly, a germinating spore establishes a multicellular network of vegetative mycelium by growing
526 through hyphal tip extension and branching. After depletion of nutrients, it undergoes autolytic
527 degradation forming aerial hyphae followed by segmentation into spore chains that will spread to start a
528 new developmental cycle [102]. Phenotypic differentiation also leads to genetic heterogeneity due to the
529 high-frequency of rearrangements and deletions [103]. Although this phenomenon was known a time ago,
530 one of the studies selected for this review linked this phenotypic differentiation to a division of labour
531 within *Streptomyces* colonies, giving rise to enhanced capacity of antibiotic production [104].

532 SMs production is also correlated with *Streptomyces* morphogenesis at the onset of sporulation, being
533 another evidence of how stress and developmental programmes are intimately connected [105]. Master
534 regulators, such as Bld (aerial hyphae formation) and Whi (spore formation) are amongst the molecular
535 mechanisms governing development, involving complex regulatory cascades [106–108]. Additionally,
536 nucleotide second messengers, such as p(p)ppGpp, cAMP, c-di-AMP and bis-(3',5')-cyclic di-guanosine
537 monophosphate (c-di-GMP), play a major role in coordinating the transition between vegetative
538 filamentous hyphae growth, reproductive aerial mycelium, and subsequent differentiation into spore
539 chains [109]. Recently, transcriptional profiles of hyper-sporulating and delayed-development mutants
540 revealed novel key genes responsive to c-di-GMP dynamics [110], discussed in another article we selected.
541 Ultimately, to understand the complex regulation of the life cycle of actinomycetes is paramount to take
542 advantage of the full potential of these antibiotic-producers' organisms. Moreover, this may be
543 considerably improved with a better understanding of the basic underlying regulatory mechanisms, an
544 area where further study is needed.

545 **Antibiotic production in *Streptomyces* is organized by a division of labor through terminal** 546 **genomic differentiation [104]**

547 Although the phenomenon of genomic instability was discovered in *Streptomyces* decades ago [111], it
548 has remained poorly understood. Zhang *et al.* describe how this genetic diversification is intertwined with
549 a division of labour in *Streptomyces* colonies, causing irreversible differentiation that gives rise to mutants
550 with enhanced antibiotic production capabilities.

551 In colonies starting from a single spore, up to 2% of cells, depending on media and growth conditions,
552 undergo vast genetic rearrangements found on both chromosomal ends that lead to an increase in
553 antibiotic production. Genome rearrangements can vary in size and frequency, while deletions can cause
554 a loss of up to 1,000 genes; amplification of regions also occurs, containing various gene copies flanked
555 by an insertion sequence (*i.e.*, IS1649, encoded by SCO0091 and SCO0368). While each mutant has a
556 unique profile of inhibition against other soil-dwelling competitors, their ability to form spores becomes
557 greatly hampered. Moreover, through these specialised mutants, the parent strain gains an advantage by
558 maximising both the colony-wide antibiotic production and its diversity.

559 The link between genomic instability and phenotypic heterogeneity was established by sequencing
560 morphologically distinct daughter colonies of *S. coelicolor* M145. Instead of reverting their morphology
561 back to wild type, as would be expected in the case of a clonal population, the progeny of aberrant
562 colonies was hypervariable. Sequencing revealed that mutants contained profound chromosomal
563 changes, involving insertions and deletions, from both arms of the chromosome. In addition, the authors
564 established an elegant method for deducing the minimal deletion size from phenotype, by linking arginine
565 auxotrophy and chloramphenicol susceptibility, by using pulse field gel electrophoresis (PFGE).
566 Furthermore, pigmented antibiotics from *S. coelicolor* M145 were used as indicators of bioactivity,
567 confirmed by overlay assays against *Bacillus subtilis*. Additional experiments of mixing spores from wild
568 type and mutant colonies in known proportions showed a strong positive correlation between the
569 percentage of mutants in the starting population and the inhibition zone size. When measuring the overall
570 spore count of such mixed colonies, no significant reduction was observed until mutants comprised up to
571 50% of the starting population, thereby neutralising the high individual fitness cost for the colony.
572 Interestingly, the final frequency of mutant spores declined to less than 1%, even if the starting proportion
573 was as high as 80%. In the future, it will be interesting to see if this phenomenon is also true for non-
574 pigmented antibiotics.

575 The work of Zhang *et al.* shows that *Streptomyces* colonies starting from a single spore become genetically
576 diverse with daughter cells specialising in specific tasks, thus providing for the first-time evidence of
577 division of labour in antibiotic production and spore formation. The molecular mechanisms regulating
578 these rearrangements remain to be discovered. Furthermore, it would be relevant to understand the cues
579 triggering these rearrangements for the manipulation of antibiotic producing strains, as they might
580 depend on external signals and/or be context dependant. We are looking forward to follow-up studies as

581 preliminary results on *Streptomyces* environmental isolates hint towards a widespread nature of such
582 division of labour.

583 **Specialized and shared functions of diguanylate cyclases and phosphodiesterases in**
584 ***Streptomyces* development [110]**

585 In *Streptomyces*, c-di-GMP is a key life cycle regulatory factor [112] that coordinates cell-fate via a complex
586 signalling network: while BldD-(c-di-GMP) acts as a transcriptional regulator of vegetative filamentous
587 growth [113]; initiation of sporulation is determined by the activity of the σ^{WhiG} RsiG-(c-di-GMP) complex
588 [114]. Turnover of the second messenger c-di-GMP is mediated by two sets of enzymes with specific
589 catalytic domains [115]: diguanylate cyclases (DGCs) that catalyse its synthesis, and phosphodiesterases
590 (PDEs) that are involved in its degradation [116].

591 Although c-di-GMP-sensors are known, there is a gap in understanding which genes are responsive to c-
592 di-GMP dynamics. Haist *et al.* aimed to unveil the specific molecular targets in two DGCs mutants ($\Delta cdgB$
593 and $\Delta cdgC$) driving hyper-sporulation, and two PDEs mutants ($\Delta rmdA$ and $\Delta rmdB$) delaying development
594 [115]. RNA-seq was used to compare mutants' transcriptional profiles with wild type *S. venezuelae*, and
595 further biochemical experiments were developed to confirm the function of the differentially expressed
596 genes.

597 Results demonstrate that c-di-GMP has a global regulatory role, antagonistically controlled by the DGCs
598 (CdgB and CdgC) and the PDEs (RmdA and RmdB). Despite observing shared enzymatic activities between
599 the two DGCs and the two PDEs, respectively; each one controls a characteristic set of genes, representing
600 unique roles in developmental regulation and thus explaining their differential phenotypes. Unexpectedly,
601 few *bld* and *whi* genes, known to be key regulators of the developmental regulatory cascade, were
602 differentially expressed in the mutant strains. On the contrary, two other categories were significantly
603 affected: the expression of the hydrophobic sheath, controlled via chaplin (*chp*) and rodlin (*rdl*) genes;
604 and the cell division components, through *ftsZ* expression.

605 Overall, Haist *et al.* demonstrate how PDEs (RmdA and RmdB), and DGCs (CdgB and CdgC) differentially
606 govern development via transcriptional BldD and σ^{WhiG} fine-tuned sensing of c-di-GMP, contributing to
607 our understanding of the c-di-GMP multilayered cascade. In addition, expression of c-di-GMP-responsive
608 genes revealed insights into how they involved in the coordinated progression of *Streptomyces*' life cycle.
609 While cell division genes control the specific timing of when spores are formed, such as *ftsZ*; the

610 determination of the sporulation mode, either being in the aerial hyphae or out of substrate mycelium, is
611 induced through chaplin and rodlin genes, which are involved in the formation of the hydrophobic sheath
612 that cover aerial hyphae and thus control where spores are developed.

613 Furthermore, a link between c-di-GMP signals and antibiotic genes expression was proposed, by studying
614 of the chloramphenicol pathway. Chloramphenicol BGC involves 17 *cml* genes [117], which were
615 significantly downregulated in the two mutants driving hyper-sporulation through the repression of *blbM*.
616 However, *cml* genes were not observed affected in the two delayed-development mutants. Recently, the
617 modulation of c-di-GMP has demonstrated to be an appealing candidate to manipulate antibiotic
618 production [118]. Thus, expanding how c-di-GMP affects other antibiotic pathways, along with the effect
619 on c-di-GMP-responsive genes remains for further investigation.

620

621 Understanding the complex regulatory networks that underlie the developmental life cycle is crucial to
622 uncover the full potential of these producer organisms. These studies show that it is fundamental to gain
623 knowledge into the molecular effectors that can trigger SMs synthesis. These insights can subsequently
624 inform metabolic engineering strategies for improved antibiotic production. Furthermore, in addition to
625 the internal regulation of SMs synthesis, biotic and abiotic environmental cues can also trigger the
626 activation of certain BGCs, leading us into the final section of this review where we focus on ecology and
627 host interactions. Deciphering actinomycete interactions either with other micro- and/or macro-
628 organisms will increase the understanding on how SMs act as signalling compounds. Moreover, a better
629 knowledge of interspecies interactions will further unlock the huge chemical diversity of actinomycete
630 SMs. Altogether, it is becoming clear that a deep understanding of all intra- and extra-cellular factors
631 affecting BGCs expression and SMs biosynthesis are necessary to further our comprehension into
632 actinomycete research.

633 IV. Ecology and Host Interactions

634 Although actinomycete are well-known as antibiotic producers, most BGCs remain silent in controlled
635 conditions [38, 102]. There is little ecological rationale for the constitutive production of these
636 energetically expensive metabolites when grown in favourable conditions such as high nutrient media.
637 Moreover, SMs production is generally under strict regulatory control, meaning that several cues
638 triggering BGCs expression can be absent or even repressed [119, 120]. However, in nature, actinomycete
639 are part of complex microbial communities and globally there is a lack of understanding of these
640 community dynamics. Additionally, actinomycete are ubiquitous in several habitats, facing ecological
641 adaptations that affect genetic determinants expression. Identifying ecologically relevant interactions is
642 further complicated when symbiosis with macro-organisms such as plants, fungi and animals is
643 considered. Overall, these interactions control the expression of actinomycete BGCs, which in turn, and
644 have played a major role in the evolution of the vast chemical diversity of SMs [121]. Co-culture
645 experiments attempt to mimic these complex relationships in the laboratory and thus elicit the production
646 of SMs [11]. Therefore, we selected one article where the co-culture approach of *Salinispora tropica* with
647 phytoplankton led to the decryption of two BGCs [122].

648 In soil, *Streptomyces* species are free-living bacteria that play an important role in decomposing of organic
649 matter by breaking down complex materials [10]. Geosmin is a widespread metabolite known long ago as
650 the responsible for conferring *Streptomyces* their earthy odour. However, until now, the ecological role
651 of geosmin was cryptic. A highlight from 2020 was that first insights into geosmin role in nature were
652 uncovered, by an article we selected that demonstrate how geosmin production is closely linked to
653 *Streptomyces* developmental cycle, where is shown that geosmin is used to attract springtails that help to
654 disperse bacterial spores over longer distances [123].

655 Additionally, actinomycete have been recognized as defensive symbionts of several invertebrate species
656 [124]. They have been shown to interact with plant roots, where they have evolved beneficial interaction
657 for protection against phytopathogens [121]. For example, *Streptomyces* can enter the root tissue and
658 enable plants to compete for food by enhancing root exudates [10]. Moreover, they can exert plant
659 growth-promoting (PGP) activities, by increasing plant biomass through direct or indirect manners, such
660 as phosphate mobilization, nitrogen fixation, iron acquisition, or enhancing the production of plant
661 hormones, to name just a few [125]. The study we have selected highlights the potential of *Streptomyces*
662 as plant probiotics in *Arabidopsis thaliana*, which can further be applied to commercial crops [126].

663 Altogether, these important interactions reflect the natural purpose of harbouring a large repertoire of
664 chemical diversity and how these SMs have evolved as a direct product of these interactions.

665

666 **Phytoplankton trigger the production of cryptic metabolites in the marine actinobacterium**
667 ***Salinispora tropica*** [122]

668 Antagonistic interactions between the marine-obligate *Salinispora tropica* and co-occurring heterotroph
669 bacteria have been previously reported [127]. The induction of antibiotic activities has been linked to
670 temporal changes in compound production composition through a complex pattern that varies regarding
671 the interaction and type of metabolites [128]. Chhun *et al.* extend this co-culturing approach by adding
672 insights into inter-species interactions between *S. tropica* and marine phototrophs. Through the
673 integration of co-culture, metabolomics and proteomic techniques, phototrophs' effect on *Salinispora*
674 BGCs expression is investigated.

675 Chhun *et al.* reported that *S. tropica* CNB-440 affects the growth of a taxonomically diverse group of
676 phytoplankton which includes the model species *Synechococcus* sp. WH7803 (cyanobacteria); *Emiliania*
677 *huxleyi* (coccolithophore); and *Phaeodactylum tricornutum* (diatom). A co-culture experiment using a
678 porous membrane to separate the organisms physically suggested that secreted metabolites of *S. tropica*
679 importantly affected *Synechococcus* sp. proliferation. Furthermore, metabolomic analyses of co-cultures
680 of *S. tropica* and *Synechococcus* sp. revealed the production of eight metabolites that were not detected
681 in axenic culture: four were related to the known compound salinosporamide, whilst the other four were
682 identified as potentially novel. As an attempt to identify BGCs overexpressed in the phototroph co-culture,
683 a comparative proteomic analysis was carried out with the proteome of *S. tropica* exposed to
684 phytoplankton photosynthate (*i.e.*, *Synechococcus* culture supernatant, rich in phototroph-released
685 nutrients). Besides confirming salinosporamide's BGCS (*sal*) overexpression, several proteins encoded in
686 orphan BGCs were detected in the photosynthate culture. A polyketide synthase (*pks3*) and a non-
687 ribosomal peptide synthetase (*nrps1*) cluster were identified as putatively responsible for metabolite
688 biosynthesis.

689 Chhun *et al.* illustrate the importance of an integrative approach in the study of actinomycete ecology. It
690 was demonstrated that metabolites produced by the rare actinomyces marine *S. tropica* CNB-440 have
691 the potential to kill both prokaryote and eukaryote phytoplankton. Although the experimental model may

692 not represent exactly the ecological interactions found in the ocean, the photosynthate cultures are a
693 good approximation to test the effect of phytoplankton over the expression of BGCs in *Salinispora*.
694 Moreover, it was shown that co-culturing phototrophs and marine-derived actinomycete could accelerate
695 the discovery of novel bioactive metabolites. Metabolomics analysis was used to identify the
696 overexpressed metabolites in co-cultures, allowing the identification of four putative candidates.
697 Metabolites potentially encoded in *nrps1* and elicited by photosynthate showed promising antimicrobial
698 activity. Unfortunately, it was not possible to link a particular overexpressed metabolite with this BGCS,
699 thus awaiting further identification. Besides expanding the knowledge on the specialised metabolites
700 produced by *Salinispora*, this study provides new insights into the ecology of actinomycete in marine
701 environments.

702 **Developmentally regulated volatiles geosmin and 2-methylisoborneol attract a soil arthropod**
703 **to *Streptomyces* bacteria promoting spore dispersal [123]**

704 Geosmin is a sesquiterpenoid metabolite known for giving soil its characteristic earthy-smelling odour,
705 produced by several actinomycete [129], amongst other microorganisms. Its biosynthesis involves a
706 geosmin synthase, which catalyses the cyclization of farnesyl diphosphate to germacrene D and
707 germacradienol, and then converts the latter to geosmin [130]. Interestingly, genes for its biosynthesis
708 are highly conserved in all *Streptomyces* genomes [131]. Similarly, genes for the biosynthesis of another
709 earthy-smell molecule, the monoterpene 2-methylisoborneol (2-MIB), are found in approximately half of
710 sequenced *Streptomyces* genomes [131]. The ubiquity of producing these volatile organic compounds
711 (VOC) in streptomycetes suggests that they confer a selective advantage. However, the benefit for the
712 producer bacteria and, therefore, geosmin's biological role remained unknown.

713 Becher *et al.* investigated the role of VOCs in the context of *Streptomyces* interaction with soil-dwelling
714 arthropods, the springtails. In field experiments, springtails showed a significant attraction to traps baited
715 with *Streptomyces coelicolor* colonies, further confirmed in laboratory Y-tube bioassay. Chemosensory
716 responses in springtail antennae gas chromatography (GC) combined with electrophysiological antennal
717 detection (EAD) revealed that geosmin, germacradienol, germacrene D, and 2-MIB induce sensory
718 responses. Mutants of these VOCs (Δ *geoA*; Δ *mibAB*; and Δ *geoA* Δ *mibAB* double mutant) demonstrated
719 that both earthy odorants are behaviourally active and serve as attractants for the springtail, guiding them
720 for localization of food sources.

721 Transcriptome analyses unveil that these VOCs are intimately connected to *Streptomyces* developmental
722 life cycle. Expression of *geoA* and *mibA-mibB* depends on the regulatory gene *blbM*, involved in aerial
723 hyphae and spore's development [132], further confirmed by lack of production of geosmin and 2-MIB in
724 a $\Delta blbM$ mutant. Interestingly, *mibA-mibB* genes were found to form an operon with *eshA*, encoding for
725 a cyclic nucleotide-binding protein of unclear function, which remains to be characterised. ChIP-seq
726 showed that BlbM directly regulates the *eshA-mibA-mibB* promoter; however, it does not regulate *geoA*
727 which instead is directly regulated by WhiH, involved in correct septation of aerial hyphae during spore
728 formation [133]. The production of both earthy odorants is directly coupled with spore formation via
729 transcriptional control of key sporulation regulators.

730 The geosmin- and 2-MIB-mediated attraction of springtails and the correlation of these VOCs to spore
731 formation suggested that springtails might act as vectors for spore dispersal. Authors confirmed this
732 observation by demonstrating that it occurs via two different routes: adherence to their body surface
733 cuticle; and passage through the gastrointestinal tract and defecation. Therefore, *Streptomyces* benefit
734 from emitting geosmin and 2-MIB as part of their developmental programme as these volatile scents guide
735 springtails to sporulating microcolonies, where they serve as vectors for spore dispersal over long
736 distances. It remains to be discovered if this relation can be also observed in another soil insects or even
737 more, expanded to other co-inhabiting animals. Further research is needed to test *Streptomyces*-
738 springtails interaction in a community context, and to explore the role of other VOCs may act as either
739 attractants or repellents for a comprehensive understanding of chemical ecological complex interactions.

740 ***Streptomyces* endophytes promote host health and enhance growth across plant species**

741 [126]

742 *Streptomyces* have been previously reported to interact with plant roots either through the rhizosphere,
743 which is the root surrounding soil; or the endophytic compartment, the niche within and between root
744 cells [125, 134]. Recent studies in *Arabidopsis thaliana* have revealed that streptomycetes are present and
745 enriched in the endophytic compartment relative to that in the bulk soil [135, 136]. Streptomycetes have
746 also been isolated from the endophytic compartment of numerous other plant species, including crops.
747 Taking together, both the ability of *Streptomyces* to colonize plant roots along with the extensive
748 repertoire of SMs, makes them interesting candidates for biocontrol in crops, with a possible application
749 as plant probiotics. To this end, Worsley *et al.* isolated *Streptomyces* endophytes from *A. thaliana* roots

750 to test the hypothesis of beneficial effects on the host and test these strains on commercial crops plants,
751 such as wheat.

752 Five strains were isolated from *A. thaliana* root microbiome (*i.e.*, L2, N1, N2, M2 and M3) and compared
753 to another three strains of the known endophyte *Streptomyces lydicus*, all selected for genome
754 sequencing. First, eGFP-tagged *Streptomyces* strains were re-infected into *A. thaliana* roots to verify the
755 ability of the endophyte to recolonise plants. Then, all the genome-sequenced strains were inoculated
756 into seedlings to investigate their effect on growth. It was observed that strains were able to colonize the
757 root surface, having a significant effect on plant biomass: strains L2, M2, and M3 gave the best
758 enhancement of dry biomass, while the three *S. lydicus* strains had no effect. Moreover, strains N1 and
759 N2 decreased *A. thaliana* growth. Interestingly, plant-treated with a mixture of L2, M2, and M3 gave
760 higher growth in comparison with individual and uninoculated controls, respectively.

761 Genome mining and bioassays of all the eight sequenced strains revealed that they produce PGP
762 compounds, including indole-3-acetic acid (IAA) and ACC deaminase. Moreover, they possess several BGCs
763 involved in siderophores and antimicrobial compounds. Among them, strain N2 shows a broad-spectrum
764 antimicrobial activity and produces filipin-like polyenes, including 14-hydroxyisochainin. N2 antifungal
765 activity was improved 2-fold in the presence of IAA, suggesting that N2 may display its activity in proximity
766 to the plant root when competing with other microbes. Additionally, coating wheat seed with N2 protects
767 the germinating seedlings from the take-all fungus *Gaeumannomyces graminis* var. *tritici*, an economically
768 important wheat pathogen.

769 In summary, this study demonstrated that introducing certain *Streptomyces* into the root microbiome
770 provides significant benefits to host plants. However, two of the five root-associated *Streptomyces* strains
771 showed a negative *in vitro* effect regarding *A. thaliana*'s biomass. Therefore, the effects of *Streptomyces*
772 strains on host plants seem to be strain-dependent, and further research is needed to understand their
773 role in these interactions. Nevertheless, the authors achieve to develop a system for studying the role of
774 SMs in nature that may provide new insights to activate silent BGCs. Specifically, they demonstrate that
775 IAA increased the antifungal activity of one of the root-associated *Streptomyces* strains, providing
776 evidence of how external signals can affect the expression of SMs. In addition, exploring plant-
777 *Streptomyces* interactions led to the identification of novel PGP and biocontrol agents that could be
778 developed as active biofertilizers, as greener alternatives to pesticides currently having a negative impact

779 in ecosystems. In future, it will be interesting to expand the testing and explore the effects of
780 *Streptomyces* in other crops.

781 **Concluding Remarks**

782 This review highlights recent research that uses integration of perspectives to further understand
783 actinomycete biology, focusing on four broad areas: *i)* technology and methodology; *ii)* specialised
784 metabolites; *iii)* development and regulation; and *iv)* ecology and host interactions.

785 In the last decade, the genomic era opened a new roadmap for the study of SMs in actinomycetes. The
786 accessible cost of whole-genome sequencing enabled the exploration of not only few, but whole
787 collections of strains. Over a relatively short period of time, the amount of available genomic data
788 increased exponentially and is bound to continue. Likewise, other omics technologies such as
789 metabolomics and transcriptomics have experienced a similar data expansion. Consequently, it is no
790 surprise that efforts are focused on developing computational tools to handle this big data. BiG-SLiCE and
791 BiG-FAM have recently expanded the BiG-SCAPE family, enabling to compare millions of BGCs, and group
792 them into gene cluster families. Moreover, additional tools such as Qemistree, which allows hierarchical
793 tree clustering based on chemical similarity; and NPLinker, that link both genomic and metabolomic data,
794 permits actinomycete research to approach old problems from a different angle, such as the rediscovery
795 of known compounds as well as prioritisation of novel BGCs.

796 In parallel to computational advances, synthetic biology tools such as a *Streptomyces* tailored cell-free
797 toolkit; and the combination of CRISPR technology with quorum sensing as a means for metabolic
798 engineering, are crucial to test the prediction-based hypotheses using wet-lab experiments. These
799 approaches will continue to increase our understanding of the role of newly characterised BGCs. This
800 information can then be stored in a database such as MIBiG, which will increase our ability to conduct
801 robust comparative studies. Additionally, synthetic biology will be a key to access silent or cryptic BGCs as
802 well as those that are found in unculturable organisms by providing controlled conditions.

803 The importance of applying these latest cutting-edge technologies to fundamental actinomycete research
804 questions has already been revealed through various major findings. This review covering just over a year
805 of research in this field offers plenty of examples such as genomic differentiation as means to achieve
806 division of labour for antibiotic production in *Streptomyces* colonies; a deeper understanding of the c-di-
807 GMP regulatory cascade and the role of the enzymes involved; the use of metabologenomics focussing
808 on a diverse phylogenetic group from polar regions and in the rare genus *Nocardia*, leading to the
809 discovery of new compounds; or using evolutionary divergence in gene clusters for prioritisation of
810 interesting BGCs, as well as the reverse approach starting from the structure of a novel metabolite to find

811 the gene cluster responsible for its production. Finally, we also highlight the impact on ecological research,
812 particularly how co-culturing can lead to the production of previously silent metabolites; how
813 *Streptomyces* can boost plant health; and discovering the environmental role of the widely distributed
814 geosmin.

815 The emergence of the SARS-CoV2 global pandemic has recently put microbiology research at the heart of
816 finding solutions for global challenges. Microbiology research will play a key role not only during the
817 current difficult times but also in tackling future pandemics and alleviating the devastating effects the
818 climate crisis will bring. Another major emergency in the making is the ever-increasing levels of drug
819 resistance. Thus, our community needs to rationally exploit the potential for discovering new compounds
820 harboured by our beloved actinomycetes and unveiling their many other secrets. Our unprecedented
821 times reflect the need for us to act as one community, collaborate by interconnecting and overlapping
822 knowledge from different research fields, and ultimately integrate them into shared solutions for common
823 problems. We hope that you can see the parallels on how integrating perspectives in the actinomycete
824 field has led to new discoveries and that there is a motivation for this to continue as a driving force in the
825 future of actinomycete research and more widely within microbiology.

826 **Conflict of interest**

827 The authors have no conflict of interest to declare.

828 **Funding information**

829 AU was supported by Comisión Nacional de Investigación Científica y Tecnológica (FONDECYT-ANID)
830 Postdoctorado N° 3180399. CFP was supported by funding of the São Paulo Research Foundation (FAPESP)
831 grant N°.2018/17502-2 and Brazilian federal funding agencies Conselho Nacional de Desenvolvimento
832 Científico e Tecnológico (CNPq) grant N°143700/2018-9. WK is supported by the Postdoctoral Research
833 Fellowship from National Center for Genetic Engineering and Biotechnology (BIOTEC), NSTDA, Thailand.
834 JP is supported by Programa de Innovación y Capital Humano para la Competitividad (PINN) of The
835 Ministry of Science, Technology and Telecommunications of Costa Rica (MICITT) grant 2-1-4-17-1-037. KV
836 has received funding from the European Union's Horizon 2020 research and innovation programme under
837 the Marie Skłodowska-Curie grant agreement No 765147. JKS is supported by Biotechnology and
838 Biological Sciences Research Council (BBSRC) grant BB/S016651/1 as PDRA.

839 **Acknowledgements**

840 We thank Sam Prudence, Beatriz Cámara and Lorena Fernández-Martínez for their helpful and
841 constructive comments on the manuscript. We also thank the Microbiology Society, for their continuous
842 support of ActinoBase.

843 **Figure Legends**

844 **Figure 1.** Integrating Perspectives in actinomycete research is accomplished by using a variety of different
845 tools covering the four research areas: Development and Regulation (DR, blue); Specialised Metabolites
846 (SM, orange); Technology and Methodology (TM, grey); and Ecology & Host Interactions (EH, yellow). The
847 colour coding is based on selected publications covered in this review.

848

849

850 **References**

- 851 1. **Prudence Samuel MM, Addington Emily, Castaño-Espriu Laia, Mark David R, Pintor-Escobar**
852 **Linamaría, Russell Alicia H, McLean Thomas C.** Advances in actinomycete research: An
853 actinobase review of 2019. *Microbiology* 2020;166:683–694.
- 854 2. **Barka Essaid Ait, Vatsa Parul, Sanchez Lisa, Gaveau-Vaillant Nathalie, Jacquard Cedric, Meier-**
855 **Kolthoff Jan P, Klenk Hans-Peter, Clément Christophe, Ouhdouch Yder, van Wezel Gilles P.**
856 Taxonomy, Physiology, and Natural Products of Actinobacteria. *Microbiol Mol Biol Rev*
857 2016;80:1–44.
- 858 3. **van der Meij Anne, Worsley Sarah F, Hutchings Matthew I, van Wezel Gilles P.** Chemical ecology
859 of antibiotic production by actinomycetes. *FEMS Microbiol Rev* 2017;41:392–416.
- 860 4. **Medema Marnix H.** Computational Genomics of Specialized Metabolism: from Natural Product
861 Discovery to Microbiome Ecology. *mSystems*;3. Epub ahead of print 2018. DOI:
862 10.1128/msystems.00182-17.
- 863 5. **Nett Markus, Ikeda Haruo, Moore Bradley S.** Genomic basis for natural product biosynthetic
864 diversity in the actinomycetes. *Nat Prod Rep* 2009;26:1362–1384.
- 865 6. **Hutchings Matt, Truman Andrew, Wilkinson Barrie.** Antibiotics: past, present and future. *Curr*
866 *Opin Microbiol* 2019;51:72–80.
- 867 7. **Craney Arryn, Ahmed Salman, Nodwell Justin.** Towards a new science of secondary metabolism.
868 *J Antibiot (Tokyo)* 2013;66:387–400.
- 869 8. **Kautsar Satria A, van der Hooft Justin JJ, de Ridder Dick, Medema Marnix H.** BiG-SLiCE: A highly
870 scalable tool maps the diversity of 1.2 million biosynthetic gene clusters. *Gigascience* 2021;10:1–
871 17.
- 872 9. **Doroghazi James R, Metcalf William W.** Comparative genomics of actinomycetes with a focus on
873 natural product biosynthetic genes. *BMC Genomics* 2013;14:611.
- 874 10. **Chater Keith F.** Recent advances in understanding *Streptomyces*. *F1000Research* 2016;5:1–16.
- 875 11. **van Bergeijk Doris A, Terlouw Barbara R, Medema Marnix H, van Wezel Gilles P.** Ecology and
876 genomics of Actinobacteria: new concepts for natural product discovery. *Nat Rev Microbiol*
877 2020;18:546–558.
- 878 12. **Baltz Richard H.** Gifted microbes for genome mining and natural product discovery. *J Ind*
879 *Microbiol Biotechnol* 2017;44:573–588.
- 880 13. **Kenshole Emma, Herisse Marion, Michael Michael, Pidot Sacha J.** Natural product discovery
881 through microbial genome mining. *Current Opinion in Chemical Biology* 2021;60:47–54.
- 882 14. **Ziemert Nadine, Alanjary Mohammad, Weber Tilmann.** The evolution of genome mining in
883 microbes-a review. *Nat Prod Rep* 2016;33:988–1005.

- 884 15. **Boddy Christopher N.** Bioinformatics tools for genome mining of polyketide and non-ribosomal
885 peptides. *Journal of Industrial Microbiology and Biotechnology* 2014;41:443–450.
- 886 16. **Amoutzias Grigoris D, Chaliotis Anargyros, Mossialos Dimitris.** Discovery Strategies of bioactive
887 compounds synthesized by nonribosomal peptide synthetases and type-I polyketide synthases
888 derived from marine microbiomes. *Marine Drugs* 2016;14:80.
- 889 17. **Gummerlich Nils, Rebets Yuriy, Paulus Constanze, Zapp Josef, Luzhetskyy Andriy.** Targeted
890 genome mining—from compound discovery to biosynthetic pathway elucidation.
891 *Microorganisms* 2020;8:1–17.
- 892 18. **Terra Luciana, Ratcliffe Norman, Castro Helena Carla, Vicente Ana Carolina Paulo, Dyson Paul.**
893 Biotechnological Potential of Streptomyces Siderophores as New Antibiotics. *Curr Med Chem*
894 2020;28:1407–1421.
- 895 19. **Aggarwal Eshani, Chauhan Srishti, Sareen Dipti.** Thiopeptides encoding biosynthetic gene
896 clusters mined from bacterial genomes. *J Biosci*;46. Epub ahead of print 1 June 2021. DOI:
897 10.1007/s12038-021-00158-2.
- 898 20. **Arnison Paul G, Bibb Mervyn J, Van Der Donk Wilfred A, et al.** Ribosomally synthesized and
899 post-translationally modified peptide natural products: Overview and recommendations for a
900 universal nomenclature. *Natural Product Reports* 2013;30:108–160.
- 901 21. **Kittrell Caroline G, Shah Shailey C, Halbert Matthew E, Scott Dylan H, Limbrick Emilianne M.**
902 Genomic analysis suggests *Salinispora* is a rich source of novel lanthipeptides. *Mol Genet*
903 *Genomics* 2020;295:1529–1535.
- 904 22. **Choudoir Mallory, Rossabi Sam, Gebert Matthew, Helmig Detlev, Fierer Noah.** A Phylogenetic
905 and Functional Perspective on Volatile Organic Compound Production by Actinobacteria .
906 *mSystems*;4. Epub ahead of print 30 April 2019. DOI: 10.1128/mSystems.00295-18.
- 907 23. **Weisskopf Laure, Schulz Stefan, Garbeva Paolina.** Microbial volatile organic compounds in intra-
908 kingdom and inter-kingdom interactions. *Nature Reviews Microbiology* 2021;19:391–404.
- 909 24. **Quinn Gerry A, Banat Aiya M, Abdelhameed Alyaa M, Banat Ibrahim M.** Streptomyces from
910 traditional medicine: sources of new innovations in antibiotic discovery. *Journal of Medical*
911 *Microbiology* 2020;69:1040–1048.
- 912 25. **Subramani Ramesh, Sijkema Detmer.** Marine rare actinomycetes: A promising source of
913 structurally diverse and unique novel natural products. *Marine Drugs*;17. Epub ahead of print
914 2019. DOI: 10.3390/md17050249.
- 915 26. **Hozzein Wael N, Mohany Mohamed, Alhawsawi Sana MM, Zaky Mohamed Y, Al-Rejaie Salim S,**
916 **Alkhalifah Dalal HM.** Flavonoids from Marine-Derived Actinobacteria as Anticancer Drugs. *Curr*
917 *Pharm Des* 2021;27:505–512.
- 918 27. **Law Jodi Woan Fei, Law Lydia Ngik Shiew, Letchumanan Vengadesh, Tan Loh Teng Hern, Wong**
919 **Sunny Hei, Chan Kok Gan, Ab Mutalib Nurul Syakima, Lee Learn Han.** Anticancer Drug Discovery
920 from Microbial Sources: The Unique Mangrove Streptomyces. *Molecules (Basel,*

- 921 *Switzerland*);25. Epub ahead of print 17 November 2020. DOI: 10.3390/molecules25225365.
- 922 28. **Hussain Aehtesham, Hassan Qazi Parvaiz, Shouche Yogesh S.** New approaches for
923 antituberculosis leads from Actinobacteria. *Drug Discovery Today* 2020;25:2335–2342.
- 924 29. **Silver Lynn L.** Challenges of antibacterial discovery. *Clin Microbiol Rev* 2011;24:71–109.
- 925 30. **Scherlach Kirstin, Hertweck Christian.** Mining and unearthing hidden biosynthetic potential. *Nat*
926 *Commun* 2021;12:1–12.
- 927 31. **Navarro-Muñoz Jorge C, Selem-Mojica Nelly, Mallowney Michael W, Kautsar Satria A, Tryon**
928 **James H, Parkinson Elizabeth I, De Los Santos Emmanuel LC, Yeong Marley, Cruz-Morales Pablo,**
929 **Abubucker Sahar, Roeters Arne, Lokhorst Wouter, Fernandez-Guerra Antonio, Cappelini**
930 **Luciana Teresa Dias, Goering Anthony W, Thomson Regan J, Metcalf William W, Kelleher Neil L,**
931 **Barona-Gomez Francisco, Medema Marnix H.** A computational framework to explore large-scale
932 biosynthetic diversity. *Nat Chem Biol* 2020;16:60–68.
- 933 32. **Crüseemann Max, O’Neill Ellis C, Larson Charles B, Melnik Alexey V., Floros Dimitrios J, Da Silva**
934 **Ricardo R, Jensen Paul R, Dorrestein Pieter C, Moore Bradley S.** Prioritizing Natural Product
935 Diversity in a Collection of 146 Bacterial Strains Based on Growth and Extraction Protocols. *J Nat*
936 *Prod* 2017;80:588–597.
- 937 33. **Medema Marnix H, et al.** Minimum Information about a Biosynthetic Gene cluster HHS Public
938 Access Author manuscript. *Nat Chem Biol* 2015;11:625–631.
- 939 34. **Kautsar Satria A, Blin Kai, Shaw Simon, Navarro-Muñoz Jorge C, Terlouw Barbara R, Van Der**
940 **Hooft Justin JJ, Van Santen Jeffrey A, Tracanna Vittorio, Suarez Duran Hernando G, Pascal**
941 **Andreu Victòria, Selem-Mojica Nelly, Alanjary Mohammad, Robinson Serina L, Lund George,**
942 **Epstein Samuel C, Sisto Ashley C, Charkoudian Louise K, Collemare Jérôme, Linington Roger G,**
943 **Weber Tilmann, Medema Marnix H.** MIBiG 2.0: A repository for biosynthetic gene clusters of
944 known function. *Nucleic Acids Res* 2020;48:D454–D458.
- 945 35. **Alam Khorshed, Hao Jinfang, Zhang Youming, Li Aiying.** Synthetic biology-inspired strategies and
946 tools for engineering of microbial natural product biosynthetic pathways. *Biotechnology*
947 *Advances*;49. Epub ahead of print 1 July 2021. DOI: 10.1016/j.biotechadv.2021.107759.
- 948 36. **Yeo Wan Lin, Heng Elena, Tan Lee Ling, Lim Yi Wee, Lim Yee Hwee, Hoon Shawn, Zhao Huimin,**
949 **Zhang Mingzi M, Wong Fong Tian.** Characterization of Cas proteins for CRISPR-Cas editing in
950 streptomycetes. *Biotechnol Bioeng* 2019;116:2330–2338.
- 951 37. **Breitling Rainer, Avbelj Martina, Bilyk Oksana, Carratore Francesco Del, Filisetti Alessandro,**
952 **Hanko Erik KR, Iorio Marianna, Redondo Rosario Pérez, Reyes Fernando, Rudden Michelle,**
953 **Severi Emmanuele, Slemc Lucija, Schmidt Kamila, Whittall Dominic R, Donadio Stefano, García**
954 **Antonio Rodríguez, Genilloud Olga, Kosec Gregor, De Lucrezia Davide, Petković Hrvoje, Thomas**
955 **Gavin, Takano Eriko.** Synthetic biology approaches to actinomycete strain improvement. *FEMS*
956 *Microbiol Lett*;368. Epub ahead of print 11 June 2021. DOI: 10.1093/femsle/fnab060.
- 957 38. **Hoskisson Paul A, Seipke Ryan F.** Cryptic or silent? The known unknowns, unknown knowns, and
958 unknown unknowns of secondary metabolism. *MBio* 2020;11:1–5.

- 959 39. **Blin Kai, Shaw Simon, Steinke Katharina, Villebro Rasmus, Ziemert Nadine, Lee Sang Yup,**
960 **Medema Marnix H, Weber Tilmann.** AntiSMASH 5.0: Updates to the secondary metabolite
961 genome mining pipeline. *Nucleic Acids Res* 2019;47:W81–W87.
- 962 40. **Skinnider Michael A, Dejong Chris A, Rees Philip N, Johnston Chad W, Li Haoxin, Webster**
963 **Andrew LH, Wyatt Morgan A, Magarvey Nathan A.** Genomes to natural products PRediction
964 Informatics for Secondary Metabolomes (PRISM). *Nucleic Acids Res* 2015;43:9645–9662.
- 965 41. **de Jong Anne, van Hijum Sacha AFT, Bijlsma Jetta JE, Kok Jan, Kuipers Oscar P.** BAGEL: A web-
966 based bacteriocin genome mining tool. *Nucleic Acids Res*;34. Epub ahead of print July 2006. DOI:
967 10.1093/nar/gkl237.
- 968 42. **Agrawal Priyesh, Khater Shradha, Gupta Money, Sain Neetu, Mohanty Debasisa.** RiPPMiner: A
969 bioinformatics resource for deciphering chemical structures of RiPPs based on prediction of
970 cleavage and cross-links. *Nucleic Acids Res* 2017;45:W80–W88.
- 971 43. **Navarro-muñoz Jorge C, Selem-mojica Nelly, Mullaney Michael W, Satria A, Tryon James H,**
972 **Parkinson Elizabeth I, Santos Emmanuel LC De Los, Yeong Marley, Cruz-morales Pablo,**
973 **Abubucker Sahar, Roeters Arne, Fernandez-guerra Antonio, Teresa Luciana, Cappelini Dias,**
974 **Anthony W, Thomson Regan J, Metcalf William W, Kelleher Neil L, Barona- Francisco.** A
975 computational framework to explore large-scale biosynthetic diversity. *Nat Chem Biol*
976 2020;16:60–68.
- 977 44. **Wang Mingxun, Carver Jeremy J, Bandeira Nuno, et al.** Sharing and community curation of mass
978 spectrometry data with Global Natural Products Social Molecular Networking. *Nature*
979 *Biotechnology* 2016;34:828–837.
- 980 45. **Kautsar Satria A, Blin Kai, Shaw Simon, Weber Tilmann, Medema Marnix H.** BiG-FAM: The
981 biosynthetic gene cluster families database. *Nucleic Acids Res* 2021;49:D490–D497.
- 982 46. **Tripathi Anupriya, Vázquez-Baeza Yoshiki, Gauglitz Julia M, Wang Mingxun, Dührkop Kai,**
983 **Nothias-Esposito Mélissa, Acharya Deepa D, Ernst Madeleine, van der Hooft Justin JJ, Zhu**
984 **Qiyun, McDonald Daniel, Brejnrod Asker D, Gonzalez Antonio, Handelsman Jo, Fleischauer**
985 **Markus, Ludwig Marcus, Böcker Sebastian, Nothias Louis Félix, Knight Rob, Dorrestein Pieter C.**
986 Chemically informed analyses of metabolomics mass spectrometry data with Qemistree. *Nat*
987 *Chem Biol* 2020;17:146–151.
- 988 47. **Medema Marnix H.** The year 2020 in natural product bioinformatics: an overview of the latest
989 tools and databases. *Nat Prod Rep.* Epub ahead of print 2021. DOI: 10.1039/D0NP00090F.
- 990 48. **Lee Namil, Hwang Soonkyu, Lee Yongjae, Cho Suhjung, Palsson Bernhard, Cho Byung Kwan.**
991 Synthetic biology tools for novel secondary metabolite discovery in *Streptomyces*. *J Microbiol*
992 *Biotechnol* 2019;29:667–686.
- 993 49. **Gust Bertholt, Chandra Govind, Jakimowicz Dagmara, Yuqing Tian, Bruton Celia J, Chater Keith**
994 **F.** REDIRECT technology: PCR-targeting system in *Streptomyces coelicolor*. In: *Advances in*
995 *Applied Microbiology*. pp. 107–126.
- 996 50. **Fernández-Martínez Lorena T, Bibb Mervyn J.** Use of the Meganuclease I-SceI of *Saccharomyces*

- 997 *cerevisiae* to select for gene deletions in actinomycetes. *Sci Rep* 2014;4:1–6.
- 998 51. **Tong Yaojun, Whitford Christopher M, Robertsen Helene L, Blin Kai, Jørgensen Tue S, Klitgaard**
999 **Andreas K, Gren Tetiana, Jiang Xinglin, Weber Tilmann, Lee Sang Yup.** Highly efficient DSB-free
1000 base editing for streptomycetes with CRISPR-BEST. *Proc Natl Acad Sci U S A* 2019;116:20366–
1001 20375.
- 1002 52. **Medema Marnix H, Breitling Rainer, Takano Eriko.** *Synthetic Biology in Streptomyces Bacteria.*
1003 1st ed. Elsevier Inc. Epub ahead of print 2011. DOI: 10.1016/b978-0-12-385075-1.00021-4.
- 1004 53. **Tian Jinzhong, Yang Gaohua, Gu Yang, Sun Xinqiang, Lu Yinhua, Jiang Weihong.** Developing an
1005 endogenous quorum-sensing based CRISPRi circuit for autonomous and tunable dynamic
1006 regulation of multiple targets in *Streptomyces*. *Nucleic Acids Res* 2020;48:8188–8202.
- 1007 54. **Mistry Jaina, Chuguransky Sara, Williams Lowri, Qureshi Matloob, Salazar Gustavo A,**
1008 **Sonhammer Erik LL, Tosatto Silvio CE, Paladin Lisanna, Raj Shriya, Richardson Lorna J, Finn**
1009 **Robert D, Bateman Alex.** Pfam: The protein families database in 2021. *Nucleic Acids Res*
1010 2021;49:D412–D419.
- 1011 55. **Zhang Tian, Ramakrishnan Raghu, Livny Miron.** *BIRCH: An Efficient Data Clustering Method for*
1012 *Very Large Databases.* 1996. Epub ahead of print 1996. DOI: 10.1145/235968.233324.
- 1013 56. **Jain Anil K.** Data clustering: 50 years beyond K-means. *Pattern Recognit Lett* 2010;31:651–666.
- 1014 57. **Blin Kai, Shaw Simon, Kautsar Satria A, Medema Marnix H, Weber Tilmann.** The antiSMASH
1015 database version 3: Increased taxonomic coverage and new query features for modular enzymes.
1016 *Nucleic Acids Res* 2021;49:D639–D643.
- 1017 58. **Palaniappan Krishnaveni, Chen I Min A, Chu Ken, Ratner Anna, Seshadri Rekha, Kyrpides Nikos**
1018 **C, Ivanova Natalia N, Mouncey Nigel J.** IMG-ABC v.5.0: An update to the IMG/Atlas of
1019 Biosynthetic Gene Clusters Knowledgebase. *Nucleic Acids Res* 2020;48:D422–D430.
- 1020 59. **Willett Peter.** Similarity-based virtual screening using 2D fingerprints. *Drug Discovery Today*
1021 2006;11:1046–1053.
- 1022 60. **Dührkop Kai, Scheubert Kerstin, Böcker Sebastian.** Molecular Formula Identification with SIRIUS.
1023 *Metabolites* 2013;3:506–516.
- 1024 61. **Dührkop Kai, Fleischauer Markus, Ludwig Marcus, Aksenov Alexander A, Melnik Alexey V.,**
1025 **Meusel Marvin, Dorrestein Pieter C, Rousu Juho, Böcker Sebastian.** SIRIUS 4: a rapid tool for
1026 turning tandem mass spectra into metabolite structure information. *Nat Methods* 2019;16:299–
1027 302.
- 1028 62. **Dührkop Kai, Shen Huibin, Meusel Marvin, Rousu Juho, Böcker Sebastian.** Searching molecular
1029 structure databases with tandem mass spectra using CSI:FingerID. *Proc Natl Acad Sci U S A*
1030 2015;112:12580–12585.
- 1031 63. **Djombou Feunang Yannick, Eisner Roman, Knox Craig, Chepelev Leonid, Hastings Janna, Owen**
1032 **Gareth, Fahy Eoin, Steinbeck Christoph, Subramanian Shankar, Bolton Evan, Greiner Russell,**

- 1033 **Wishart David S.** ClassyFire: automated chemical classification with a comprehensive,
1034 computable taxonomy. *J Cheminform* 2016;8:1–20.
- 1035 64. **Letunic Ivica, Bork Peer, Gmbh Biobyte Solutions.** Interactive Tree Of Life (iTOL) v5 : an online
1036 tool for phylogenetic tree display and annotation. 2021;1–4.
- 1037 65. **Bolyen Evan, Rideout Jai Ram, Caporaso J Gregory, et al.** Reproducible, interactive, scalable and
1038 extensible microbiome data science using QIIME 2. *Nature Biotechnology* 2019;37:852–857.
- 1039 66. **Aron Allegra T, Gentry Emily C, McPhail Kerry L, Nothias Louis Félix, Nothias-Esposito Mélissa,**
1040 **Bouslimani Amina, Petras Daniel, Gauglitz Julia M, Sikora Nicole, Vargas Fernando, van der**
1041 **Hooft Justin JJ, Ernst Madeleine, Kang Kyo Bin, Aceves Christine M, Caraballo-Rodríguez Andrés**
1042 **Mauricio, Koester Irina, Weldon Kelly C, Bertrand Samuel, Roullier Catherine, Sun Kunyang,**
1043 **Tehan Richard M, Boya P Christopher A, Christian Martin H, Gutiérrez Marcelino, Ulloa Aldo**
1044 **Moreno, Tejeda Mora Javier Andres, Mojica-Flores Randy, Lakey-Beitia Johant, Vásquez-Chaves**
1045 **Victor, Zhang Yilue, Calderón Angela I, Tayler Nicole, Keyzers Robert A, Tugizimana Fidele,**
1046 **Ndlovu Nombuso, Aksenov Alexander A, Jarmusch Alan K, Schmid Robin, Truman Andrew W,**
1047 **Bandeira Nuno, Wang Mingxun, Dorrestein Pieter C.** Reproducible molecular networking of
1048 untargeted mass spectrometry data using GNPS. *Nat Protoc* 2020;15:1954–1991.
- 1049 67. **LR Thompson, JG Sanders, D McDonald, A Amir, J Ladau, KJ Locey, RJ Prill, A Tripathi, SM**
1050 **Gibbons, G Ackermann, JA Navas-Molina, S Janssen, E Kopylova, Y Vázquez-Baeza, A González,**
1051 **JT Morton, S Mirarab, Z Zech Xu, L Jiang, MF Haroon, J Kanbar, Q Zhu, S Jin Song, T Kosciolk,**
1052 **NA Bokulich, J Lefler, CJ Brislawn, G Humphrey, SM Owens, J Hampton-Marcell, D Berg-Lyons, V**
1053 **McKenzie, N Fierer, JA Fuhrman, A Clauset, RL Stevens, A Shade, KS Pollard, KD Goodwin, JK**
1054 **Jansson, JA Gilbert, R Knight.** A communal catalogue reveals Earth’s multiscale microbial
1055 diversity. *Nature* 2017;551:457–463.
- 1056 68. **Moore Simon J, Lai Hung-En, Chee Soo-Mei, Toh Ming, Coode Seth, Chengan Kameshwari,**
1057 **Capel Patrick, Corre Christophe, de los Santos Emmanuel LC, Freemont Paul S.** A *Streptomyces*
1058 *venezuelae* Cell-Free Toolkit for Synthetic Biology. *ACS Synth Biol*. Epub ahead of print 2021. DOI:
1059 10.1021/acssynbio.0c00581.
- 1060 69. **Lu Yuan.** Cell-free synthetic biology: Engineering in an open world. *Synth Syst Biotechnol*
1061 2017;2:23–27.
- 1062 70. **Caschera Filippo, Noireaux Vincent.** Synthesis of 2.3 mg/ml of protein with an all *Escherichia coli*
1063 cell-free transcription-translation system. *Biochimie* 2014;99:162–168.
- 1064 71. **Kuruma Yutetsu, Ueda Takuya.** The PURE system for the cell-free synthesis of membrane
1065 proteins. *Nat Protoc* 2015;10:1328–1344.
- 1066 72. **Lavickova Barbora, Maerkl Sebastian J.** A Simple, Robust, and Low-Cost Method to Produce the
1067 PURE Cell-Free System. *ACS Synth Biol* 2019;8:455–462.
- 1068 73. **Rutledge Peter J, Challis Gregory L.** Discovery of microbial natural products by activation of silent
1069 biosynthetic gene clusters. *Nat Rev Microbiol* 2015;13:509–523.
- 1070 74. **Cress Brady F, Trantas Emmanouil A, Ververidis Filippos, Linhardt Robert J, Koffas Mattheos**

- 1071 **AG.** Sensitive cells: Enabling tools for static and dynamic control of microbial metabolic
1072 pathways. *Current Opinion in Biotechnology* 2015;36:205–214.
- 1073 75. **Hartline Christopher J, Schmitz Alexander C, Han Yichao, Zhang Fuzhong.** Dynamic control in
1074 metabolic engineering: Theories, tools, and applications. *Metabolic Engineering* 2021;63:126–
1075 140.
- 1076 76. **Takano Eriko.** γ -Butyrolactones: *Streptomyces* signalling molecules regulating antibiotic
1077 production and differentiation. *Current Opinion in Microbiology* 2006;9:287–294.
- 1078 77. **Nishida Hiromi, Ohnishi Yasuo, Beppu Teruhiko, Horinouchi Sueharu.** Evolution of γ -
1079 butyrolactone synthases and receptors in *Streptomyces*. *Environ Microbiol* 2007;9:1986–1994.
- 1080 78. **Malpartida Francisco, Hopwood David A.** Physical and genetic characterisation of the gene
1081 cluster for the antibiotic actinorhodin in *Streptomyces coelicolor* A3(2). *Mol Gen Genet*
1082 1986;205:66–73.
- 1083 79. **Tiwari Kavita, Gupta Rajinder K.** Diversity and isolation of rare actinomycetes: An overview. *Crit*
1084 *Rev Microbiol* 2013;39:256–294.
- 1085 80. **Subramani Ramesh, Sipkema Detmer.** Marine rare actinomycetes: A promising source of
1086 structurally diverse and unique novel natural products. *Mar Drugs* 2019;17:249.
- 1087 81. **Román-Ponce Brenda, Millán-Aguiñaga Natalie, Guillen-Matus Dulce, Chase Alexander B,**
1088 **Ginigini Joape GM, Soapi Katy, Feussner Klaus D, Jensen Paul R, Trujillo Martha E.** Six novel
1089 species of the obligate marine actinobacterium *Salinispora*, *Salinispora cortesiana* sp. nov.,
1090 *Salinispora fenicalii* sp. nov., *Salinispora goodfellowii* sp. nov., *Salinispora mooreana* sp. nov.,
1091 *Salinispora oceanensis* sp. nov. and *Salinispora vitien*. *Int J Syst Evol Microbiol* 2020;70:4668–
1092 4682.
- 1093 82. **Kim Haerin, Kim Sohee, Kim Minju, Lee Chaeyoung, Yang Inho, Nam Sang Jip.** Bioactive natural
1094 products from the genus *Salinispora*: a review. *Arch Pharm Res* 2020;43:1230–1258.
- 1095 83. **Millán-Aguiñaga Natalie, Soldatou Sylvia, Brozio Sarah, Munnoch John T, Howe John, Hoskisson**
1096 **Paul A, Duncan Katherine R.** Awakening ancient polar actinobacteria: Diversity, evolution and
1097 specialized metabolite potential. *Microbiol (United Kingdom)* 2019;165:1169–1180.
- 1098 84. **Axenov-Gribanov Denis V., Voytsekhovskaya Irina V., Tokovenko Bogdan T, Protasov Eugeny S,**
1099 **Gamaiunov Stanislav V., Rebets Yuriy V., Luzhetskyy Andriy N, Timofeyev Maxim A.**
1100 Actinobacteria isolated from an underground lake and moonmilk speleothem from the biggest
1101 conglomeratic karstic cave in Siberia as sources of novel biologically active compounds. *PLoS One*
1102 2016;11:1–12.
- 1103 85. **Adam Delphine, Maciejewska Marta, Naômé Aymeric, Martinet Loïc, Coppieters Wouter, Karim**
1104 **Latifa, Baurain Denis, Rigali Sébastien.** Isolation, characterization, and antibacterial activity of
1105 hard-to-culture actinobacteria from cave moonmilk deposits. *Antibiotics* 2018;7:1–20.
- 1106 86. **Long Yunchuan, Jiang Juan, Hu Xuejun, Zhou Juan, Hu Jing, Zhou Shaoqi.** Actinobacterial
1107 community in Shuanghe Cave using culture-dependent and -independent approaches. *World J*

- 1108 *Microbiol Biotechnol*;35. Epub ahead of print 2019. DOI: 10.1007/s11274-019-2713-y.
- 1109 87. **Sayed AM, Hassan MHA, Alhadrami HA, Hassan HM, Goodfellow M, Rateb ME.** Extreme
1110 environments: microbiology leading to specialized metabolites. *Journal of Applied Microbiology*
1111 2020;128:630–657.
- 1112 88. **Goodfellow Michael, Nouioui Imen, Sanderson Roy, Xie Feiyang, Bull Alan T.** Rare taxa and dark
1113 microbial matter: novel bioactive actinobacteria abundant in Atacama Desert soils. *Antonie van*
1114 *Leeuwenhoek, International Journal of General and Molecular Microbiology* 2018;111:1315–
1115 1332.
- 1116 89. **Benaud Nicole, Edwards Richard J, Amos Timothy G, D’Agostino Paul M, Gutiérrez-Chávez**
1117 **Carolina, Montgomery Kate, Nicetic Iskra, Ferrari Belinda C.** Antarctic desert soil bacteria exhibit
1118 high novel natural product potential, evaluated through long-read genome sequencing and
1119 comparative genomics. *Environ Microbiol.* Epub ahead of print 2020. DOI: 10.1111/1462-
1120 2920.15300.
- 1121 90. **Männle Daniel, McKinnie Shaun MK, Mantri Shrikant S, Steinke Katharina, Lu Zeyin, Moore**
1122 **Bradley S, Ziemert Nadine, Kaysser Leonard.** Comparative Genomics and Metabolomics in the
1123 Genus *Nocardia*. *mSystems* 2020;5:1–19.
- 1124 91. **Soldatou Sylvia, Eldjárn Grímur Hjörleifsson, Ramsay Andrew, van der Hooft Justin JJ, Hughes**
1125 **Alison H, Rogers Simon, Duncan Katherine R.** Comparative Metabologenomics Analysis of Polar
1126 Actinomycetes. *Mar Drugs* 2021;19:103.
- 1127 92. **Culp Elizabeth J, Waglechner Nicholas, Wang Wenliang, Fiebig-Comyn Aline A, Hsu Yen Pang,**
1128 **Koteva Kalinka, Sychantha David, Coombes Brian K, Van Nieuwenhze Michael S, Brun Yves V.,**
1129 **Wright Gerard D.** Evolution-guided discovery of antibiotics that inhibit peptidoglycan
1130 remodelling. *Nature* 2020;578:582–587.
- 1131 93. **Zdouc Mitja M, Alanjary Mohammad M, Zarazúa Guadalupe S, Maffioli Sonia I, Crüsemann**
1132 **Max, Medema Marnix H, Donadio Stefano, Sosio Margherita.** A biaryl-linked tripeptide from
1133 *Planomonospora* reveals a widespread class of minimal RiPP gene clusters. *Cell Chem Biol*
1134 2021;1–7.
- 1135 94. **Van Der Hooft Justin JJ, Mohimani Hosein, Bauermeister Anelize, Dorrestein Pieter C, Duncan**
1136 **Katherine R, Medema Marnix H.** Linking genomics and metabolomics to chart specialized
1137 metabolic diversity. *Chem Soc Rev* 2020;49:3297–3314.
- 1138 95. **Eldjárn Grímur Hjörleifsson, Ramsay Andrew, van der Hooft Justin JJ, Duncan Katherine R,**
1139 **Soldatou Sylvia, Rousu Juho, Daly Rónán, Wandy Joe, Rogers Simon.** Ranking microbial
1140 metabolomic and genomic links in the NPLinker framework using complementary scoring
1141 functions. *bioRxiv* 2020;2020.06.12.148205.
- 1142 96. **Ernst Madeleine, Kang Kyo Bin, Nothias Louis-felix, Wandy Joe, Chen Christopher, Wang**
1143 **Mingxun, Rogers Simon, Medema Marnix H, Dorrestein Pieter C, Hooft Justin JJ Van Der.**
1144 MolNetEnhancer : Enhanced Molecular Networks by Integrating Metabolome Mining and
1145 Annotation Tools.

- 1146 97. **Medema Marnix H, Kottmann Renzo, Glöckner Frank Oliver, et al.** The Minimum Information
1147 about a Biosynthetic Gene cluster (MIBiG) specification. *Nat Chem Biol* 2015;11:625–631.
- 1148 98. **Waglechner Nicholas, McArthur Andrew G, Wright Gerard D.** Phylogenetic reconciliation reveals
1149 the natural history of glycopeptide antibiotic biosynthesis and resistance. *Nat Microbiol*
1150 2019;4:1862–1871.
- 1151 99. **Blackman Steve A, Smith Thomas J, Foster Simon J.** The role of autolysins during vegetative
1152 growth of *Bacillus subtilis* 168. *Microbiology* 1998;144:73–82.
- 1153 100. **Funk Michael A, Donk Wilfred A Van Der.** Ribosomal Natural Products, Tailored To Fit. Epub
1154 ahead of print 2017. DOI: 10.1021/acs.accounts.7b00175.
- 1155 101. **Zdouc Mitja M, Iorio Marianna, Maffioli Sonia I, Crüsemann Max, Donadio Stefano, Sosio**
1156 **Margherita.** *Planomonospora* : A Metabolomics Perspective on an Underexplored Actinobacteria
1157 Genus. *J Nat Prod* 2021;acs.jnatprod.0c00807.
- 1158 102. **van der Meij Anne, Worsley Sarah F, Hutchings Matthew I, van Wezel Gilles P.** Chemical ecology
1159 of antibiotic production by actinomycetes. *FEMS Microbiology Reviews* 2017;41:392–416.
- 1160 103. **Chen Carton W, Huang Chih Hung, Lee Hsuan Hsuan, Tsai Hsiu Hui, Kirby Ralph.** Once the circle
1161 has been broken: Dynamics and evolution of *Streptomyces* chromosomes. *Trends Genet*
1162 2002;18:522–529.
- 1163 104. **Zhang Zheren, Du Chao, de Barsey Frederique, Liem Michael, Liakopoulos Apostolos, van Wezel**
1164 **Gilles P, Choi Young H, Claessen Dennis, Rozen Daniel E.** Antibiotic production in *Streptomyces* is
1165 organized by a division of labour through terminal genomic differentiation. *bioRxiv* 2019;1–10.
- 1166 105. **Kelemen Gabriella H, Viollier Patrick H, Tenor Jennifer L, Marri Laura, Buttner Mark J,**
1167 **Thompson Charles J.** A connection between stress and development in the multicellular
1168 prokaryote *Streptomyces coelicolor* A3(2). *Mol Microbiol* 2001;40:804–814.
- 1169 106. **McLean Thomas C, Lo Rebecca, Tschowri Natalia, Hoskisson Paul A, Al Bassam Mahmoud M,**
1170 **Hutchings Matthew I, Som Nicolle F.** Sensing and responding to diverse extracellular signals: An
1171 updated analysis of the sensor kinases and response regulators of *Streptomyces* species.
1172 *Microbiol (United Kingdom)* 2019;165:929–952.
- 1173 107. **McCormick Joseph R, Flärdh Klas.** Signals and regulators that govern *Streptomyces* development.
1174 *FEMS Microbiol Rev* 2012;36:206–231.
- 1175 108. **Hutchings Matthew I, Hoskisson Paul A, Chandra Govind, Buttner Mark J.** Sensing and
1176 responding to diverse extracellular signals? Analysis of the sensor kinases and response
1177 regulators of *Streptomyces coelicolor* A3(2). *Microbiology* 2004;150:2795–2806.
- 1178 109. **Latoscha Andreas, Wörmann Mirka E, Tschowri Natalia.** Nucleotide second messengers in
1179 *Streptomyces*. *Microbiol (United Kingdom)* 2019;165:1153–1165.
- 1180 110. **Haist Julian, Neumann Sara Alina, Al-Bassam Mahmoud M, Lindenberg Sandra, Elliot Marie A,**
1181 **Tschowri Natalia.** Specialized and shared functions of diguanylate cyclases and

- 1182 phosphodiesterases in *Streptomyces* development. *Mol Microbiol* 2020;114:808–822.
- 1183 111. **Dyson P, Schrempf H.** Genetic instability and DNA amplification in *Streptomyces lividans* 66. *J*
1184 *Bacteriol* 1987;169:4796–4803.
- 1185 112. **Bush Matthew J, Tschowri Natalia, Schlimpert Susan, Flärdh Klas, Buttner Mark J.** C-di-GMP
1186 signalling and the regulation of developmental transitions in streptomycetes. *Nat Rev Microbiol*
1187 2015;13:749–760.
- 1188 113. **Tschowri Natalia, Schumacher Maria A, Schlimpert Susan, Chinnam Naga Babu, Findlay Kim C,**
1189 **Brennan Richard G, Buttner Mark J.** Tetrameric c-di-GMP mediates effective transcription factor
1190 dimerization to control *Streptomyces* development. *Cell* 2014;158:1136–1147.
- 1191 114. **Gallagher Kelley A, Schumacher Maria A, Bush Matthew J, Bibb Maureen J, Chandra Govind,**
1192 **Holmes Neil A, Zeng Wenjie, Henderson Max, Zhang Hengshan, Findlay Kim C, Brennan Richard**
1193 **G, Buttner Mark J.** c-di-GMP Arms an Anti- σ to Control Progression of Multicellular
1194 Differentiation in *Streptomyces*. *Mol Cell* 2020;77:586-599.e6.
- 1195 115. **Al-Bassam Mahmoud M, Haist Julian, Neumann Sara Alina, Lindenberg Sandra, Tschowri**
1196 **Natalia.** Expression patterns, genomic conservation and input into developmental regulation of
1197 the GGDEF/EAL/HD-GYP domain proteins in *Streptomyces*. *Front Microbiol* 2018;9:1–11.
- 1198 116. **Jenal Urs, Reinders Alberto, Lori Christian.** Cyclic di-GMP: Second messenger extraordinaire. *Nat*
1199 *Rev Microbiol* 2017;15:271–284.
- 1200 117. **Fernández-Martínez Lorena T, Borsetto Chiara, Gomez-Escribano Juan Pablo, Bibb Maureen J,**
1201 **Al-Bassam Mahmoud M, Chandra Govind, Bibb Mervyn.** New insights into chloramphenicol
1202 biosynthesis in *Streptomyces venezuelae* ATCC 10712. *Antimicrob Agents Chemother*
1203 2014;58:7441–7450.
- 1204 118. **Makitrynsky Roman, Tsyplik Olga, Nuzzo Desirée, Paululat Thomas, Zechel David L, Bechthold**
1205 **Andreas.** Secondary nucleotide messenger c-di-GMP exerts a global control on natural product
1206 biosynthesis in streptomycetes. *Nucleic Acids Res* 2020;48:1583–1598.
- 1207 119. **Van Wezel Gilles P, McDowall Kenneth J.** The regulation of the secondary metabolism of
1208 *Streptomyces*: New links and experimental advances. *Nat Prod Rep* 2011;28:1311–1333.
- 1209 120. **van der Heul Helga, Bilyk Bohdan, McDowall Kenneth, Seipke Ryan, van Wezel Gilles.**
1210 Regulation of antibiotic production in Actinobacteria: new perspectives from the post-genomic
1211 era. *Nat Prod Rep* 2018;35:575–604.
- 1212 121. **Seipke Ryan F, Kaltenpoth Martin, Hutchings Matthew I.** *Streptomyces* as symbionts: An
1213 emerging and widespread theme? *FEMS Microbiol Rev* 2012;36:862–876.
- 1214 122. **Chhun Audam, Sousoni Despoina, Aguiló-Ferretjans Maria del Mar, Song Lijiang, Corre**
1215 **Christophe, Christie-Oleza Joseph A.** Phytoplankton trigger the production of cryptic metabolites
1216 in the marine actinobacterium *Salinispora tropica*. *Microb Biotechnol*. Epub ahead of print 2020.
1217 DOI: 10.1111/1751-7915.13722.

- 1218 123. **Becher Paul G, Verschut Vasiliki, Bibb Maureen J, Bush Matthew J, Molnár Béla P, Barane**
1219 **Elisabeth, Al-Bassam Mahmoud M, Chandra Govind, Song Lijiang, Challis Gregory L, Buttner**
1220 **Mark J, Flärdh Klas.** Developmentally regulated volatiles geosmin and 2-methylisoborneol attract
1221 a soil arthropod to *Streptomyces* bacteria promoting spore dispersal. *Nat Microbiol* 2020;5:821–
1222 829.
- 1223 124. **Kaltenpoth Martin.** Actinobacteria as mutualists: general healthcare for insects? *Trends*
1224 *Microbiol* 2009;17:529–535.
- 1225 125. **Viaene Tom, Langendries Sarah, Beirinckx Stien, Maes Martine, Goormachtig Sofie,**
1226 **Rhizobacteria Growth-promoting.** *Streptomyces* as a plant's best friend? 2016;1–10.
- 1227 126. **Worsley Sarah F, Newitt Jake, Rassbach Johannes, Batey Sibyl FD, Holmes Neil A, Murrell J**
1228 **Colin, Wilkinson Barrie, Hutchings Matthew I.** *Streptomyces* endophytes promote host health
1229 and enhance growth across plant species. *Appl Environ Microbiol* 2020;86:1–17.
- 1230 127. **Patin Nastassia V., Duncan Katherine R, Dorrestein Pieter C, Jensen Paul R.** Competitive
1231 strategies differentiate closely related species of marine actinobacteria. *ISME J* 2016;10:478–490.
- 1232 128. **Patin Nastassia V., Floros Dimitrios J, Hughes Chambers C, Dorrestein Pieter C, Jensen Paul R.**
1233 The role of inter-species interactions in *Salinispora* specialized metabolism. *Microbiol (United*
1234 *Kingdom)* 2018;164:946–955.
- 1235 129. **Gerber NN, Lechevalier HA.** Geosmin, an Earthy-Smelling Substance Isolated from
1236 Actinomycetes. *Appl Microbiol* 1965;13:935–938.
- 1237 130. **Jiang Jiaoyang, He Xiaofei, Cane David.** Biosynthesis of the earthy odorant geosmin by a
1238 bifunctional *Streptomyces coelicolor* enzyme. *Nat Chem Biol* 2007;3:711–715.
- 1239 131. **Rabe Patrick, Citron Christian A, Dickschat Jeroen S.** Volatile terpenes from actinomycetes: A
1240 biosynthetic study correlating chemical analyses to genome data. *ChemBioChem* 2013;14:2345–
1241 2354.
- 1242 132. **Al-Bassam Mahmoud M, Bibb Maureen J, Bush Matthew J, Chandra Govind, Buttner Mark J.**
1243 Response Regulator Heterodimer Formation Controls a Key Stage in *Streptomyces* Development.
1244 *PLoS Genet*;10. Epub ahead of print 2014. DOI: 10.1371/journal.pgen.1004554.
- 1245 133. **Persson Jessica, Chater Keith F, Flärdh Klas.** Molecular and cytological analysis of the expression
1246 of *Streptomyces* sporulation regulatory gene *whiH*. *FEMS Microbiol Lett* 2013;341:96–105.
- 1247 134. **Schrey Silvia D, Tarkka Mika T.** Friends and foes: Streptomyces as modulators of plant disease
1248 and symbiosis. *Antonie van Leeuwenhoek, Int J Gen Mol Microbiol* 2008;94:11–19.
- 1249 135. **Bulgarelli Davide, Rott Matthias, Schlaeppi Klaus, Ver Loren van Themaat Emiel, Ahmadinejad**
1250 **Nahal, Assenza Federica, Rauf Philipp, Huettel Bruno, Reinhardt Richard, Schmelzer Elmon,**
1251 **Peplies Joerg, Gloeckner Frank Oliver, Amann Rudolf, Eickhorst Thilo, Schulze-Lefert Paul.**
1252 Revealing structure and assembly cues for *Arabidopsis* root-inhabiting bacterial microbiota.
1253 *Nature* 2012;488:91–95.

1254 136. **Lundberg Derek S, Lebeis Sarah L, Paredes Sur Herrera, Yourstone Scott, Gehring Jase, Malfatti**
1255 **Stephanie, Tremblay Julien, Engelbrektsen Anna, Kunin Victor, Rio Tijana Glavina Del, Edgar**
1256 **Robert C, Eickhorst Thilo, Ley Ruth E, Hugenholtz Philip, Tringe Susannah Green, Dangl Jeffery**
1257 **L. Defining the core *Arabidopsis thaliana* root microbiome. *Nature* 2012;488:86–90.**

1258